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Per Aspera Ad Astra 
  
ABSTRACT 
Background and aims: 
Thrombolysis is in common use in the treatment of acute forms of vascular disease. It may be 
used both systemically and locally, in the latter case through an endovascular approach, so-
called catheter-directed thrombolysis.  
The aims of this thesis were to investigate how thrombolysis affects performance-related 
outcomes pertaining to vascular patency after thrombolysis, and how it affects patient safety 
and the development of complications.  
Methods: Retrospective reviews of patient medical records (all studies) and of data collected 
from the national stroke and vascular surgery registries (Study II). Study I investigated the 
outcomes of thrombolysis after infrainguinal bypass graft occlusion in 123 consecutive 
patients. In Study II, the safety-related outcomes after carotid endarterectomy and stenting 
(CEA and CAS) were evaluated in 79 patients having undergone systemic thrombolysis for 
stroke, and this cohort was compared with the 3,998 patients treated by the same methods but 
without preceding thrombolysis. In Study III, 149 episodes of dialysis access occlusion 
treated by open surgery or thrombolysis were investigated concerning patency and risks of 
rethrombosis. Study IV assessed the influence of patient level of care during catheter-directed 
thrombolysis for limb ischaemia and dialysis access thrombosis on safety-related outcomes, 
and investigated possible risk factors for patient transfer to a higher level of care.  
Results: 
In Study I, technical success of CDT was achieved in 85% of cases with an amputation-free 
survival of 89% and 75% at one and 12 months. Higher age and acute critical limb ischaemia 
were adversely associated with amputation-free survival. Synthetic grafts had a tendency 
toward reduced amputation-free survival. Study II showed a similar stroke and death rate 
following CEA/CAS for patients having undergone systemic thrombolysis compared with 
those who had not (2.5% versus 3.8%, P=0.55). There was no significant increase in bleeding 
complications in the thrombolysis cohort (3.8% versus 3.3%, P=0.79). In Study III, CDT of 
native and prosthetic dialysis accesses yielded a decreased risk of rethrombosis (HR 0.41; 
95% CI 0.04-0.98) and native fistulas exhibited better patency both after CDT and open 
surgery. The complication rate was 2.7% (infection only; there was no death, stroke, severe 
bleeding or myocardial infarction). Study IV showed no differences in the rate of 
complications (including major bleeding, myocardial infarction and stroke) in patients on the 
general vascular ward compared with those under a higher level of care on the postoperative 
recovery unit. Cardiac disease was an independent risk factor for patient transfer to a higher 
level of care. 
Conclusions: 
CDT yields good results in terms of technical success and amputation-free survival both in 
the short and medium term after treatment of infrainguinal bypass graft occlusion. Prior 
systemic thrombolysis seems not to increase the periprocedural risk of CEA or CAS in 
patients with symptomatic  carotid artery stenosis. CDT reduces the risk of rethrombosis both 
for native and prosthetic fistulas after access thrombosis even after accounting for adjunctive 
procedures (undertaken more frequently in those undergoing CDT). Care on a general 
vascular ward appears safe in the context of CDT. Nonetheless, preexisting cardiac disease 
was shown to increase the risk of transfer and highlights the importance of appropriate patient 
selection.   
Thrombolysis is associated with safe and efficaceous treatment of many groups of vascular 
surgical patients. However, continuous evaluation of outcomes is required in view of the 
rapid development of endovascular techniques and devices, and further work should also be 
done on medical adjunctive management in order to maximise vascular patency after 
successful thrombolysis.  
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1 INTRODUCTION 
 
1.1  BACKGROUND 
 
Thrombolysis (from the Greek words thrombos, meaning lump or clot, and lysis, meaning 
loosening) is the process whereby a blood clot is dissolved through the enzymatic degradation of 
the fibrin mesh that provides it with its structural stability. Today, the term is generally used to 
describe the pharmacological induction of clot lysis for the treatment of vascular embolism or 
thrombosis.  
Thrombolysis has been in clinical use since the 1940s, when Garner and Tillett1 published the 
first work detailing the effect of injecting streptokinase (SK), a thrombolytic substance, into the 
thick, liquefied pleural effusions of patients with empyema. Since then, the intravenous 
administration of thrombolytics, so-called systemic thrombolysis, has been used for the 
treatment of both myocardial infarction (AMI) and stroke. However, systemic thrombolysis is, 
as the name suggests, non-specific in terms of drug delivery and alternative methods have 
subsequently been developed to increase therapeutic precision and reduce the risk of unwanted 
side-effects.  
In 1974, Dotter and colleagues described for the first time the placement of an intra-arterial 
catheter for the selective, continuous deposition of SK into the occluded target vessel in the 
treatment of 17 patients with lower extremity thrombo-embolism.2 In this very early series of 
what is now known as catheter-directed thrombolysis (CDT), clot lysis (as confirmed by 
angiography) was achieved in 12 of 17 cases. Subsequently, there has been significant 
development of both thrombolytic drugs and endovascular techniques3, which has led to a steady 
increase in the use of CDT, in particular in the treatment of lower limb ischaemia. 
Today, CDT is used by vascular surgeons, interventional cardiologists, neuroradiologists and 
interventional radiologists in the treatment of all forms of vascular disease.  
 
1.2 THROMBOLYSIS – THROMBOLYTICS 
 
1.2.1 Thrombosis and embolism 
The acute occlusion of a blood vessel due to clot formation can have devastating physiological 
consequences. Time is of the essence in order to minimise tissue ischaemia and thus minimise 
tissue damage or loss. Atraumatic vessel occlusion may be a result either of transportation of a 
preformed thrombus (e.g. from the heart) that commonly lodges at a junction or a site of 
narrowing in the vessel, leading to its occlusion (known as embolisation), or it may be due to 
thrombus formation secondary to the rupture of an atherosclerotic plaque, which causes platelet 
adhesion, activation of the clotting cascade and, eventually, the formation of a clot (known as 
thrombosis).  
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The formation of a thrombus is initiated by platelet activation through exposure of 
subendothelial collagen, which causes glycoproteins (GPIb, IV, V, IX) on the platelet surface to 
interact directly with the collagen; through collagen-bound von Willebrand factor, leading to 
platelet adhesion and activation; or through direct activation of platelets through tissue factor 
(TF). Through interactions with factors VIIa and factor IX, this pathway leads to the generation 
of thrombin and thereby activation of platelets4 and conversion of fibrinogen to fibrin 
monomers. These monomers then polymerise into a stable matrix that provides the thrombus 
with a scaffold.5 The fibrin content of a thrombus appears to be correlated to ischaemic time6, 
which suggests that time is a variable affecting the stability and structure of the fibrin matrix.   
1.2.2 Fibrinolysis 
In vivo, the breakdown of fibrin is activated by endogenously produced tissue plasminogen 
activator (t-PA) and urokinase-type plasminogen activator (u-PA). These are produced mainly 
by endothelial cells, and their activity is strictly regulated by inhibitors of plasminogen activators 
such as plasminogen activator inhibitor-1 (PAI-1) and by direct plasmin inhibitors (such as α1-
antiplasmin and α2-macroglobulin).7 In vivo, fibrinolysis is therefore a very localised and highly 
regulated process. t-PA binds to fibrin, which leads to a conversion of fibrin-bound plasminogen 
to plasmin. The action of t-PA is therefore relatively clot-specific. Figure 1 shows a schematic 
outline of the process.  
Figure 1: Schematic representation of the fibrinolytic process (adapted from Banerjee et al.8) 
  
   9 
1.2.3 Fibrinolytic drugs 
The first fibrinolytic substance was discovered in the first half of the 1930s9, when it was 
observed that some strains of haemolytic streptococci were able to liquefy human fibrin clot. 
Almost 10 years later it was elucidated that the so-called ‘streprococcal fibrinolysin’ did not, in 
fact, directly cause the disintegration of the fibrin, but acted as a proteolytic enzyme cleaving an 
endogenous substrate, which then caused fibrinolysis.10 
The substance was subsequently named streptokinase (SK), and was first used therapeutically to 
liquefy the congealed pleural effusions seen in empyema.1 SK works by unselectively binding to 
plasminogen, forming a complex that can catalyse the change from plasminogen to plasmin. It 
therefore has an effect both on circulating plasminogen as well as plasminogen bound to fibrin, 
and thereby induces systemic plasminaemia. SK has subsequently been used in the treatment of 
both acute myocardial infarction11 and lower extremity ischaemia.12  
Although SK is an effective fibrinolytic, its antigenicity (secondary to its bacterial origin) can 
cause significant side-effects (hypotension and allergic reactions, to mention the most common) 
in patients, which limits its use. Moreover, the unselective nature of the plasminogen activation 
may increase the risk of haemorrhage.3 
 
Urokinase (UK) was subsequently isolated from human urine in the 1950s. Unlike SK, UK is 
non-antigenic13 but possesses similar fibrinolytic activity. Compared with SK, UK has an 
increased affinity for fibrin-bound plasminogen, thereby reducing systemic fibrinolysis.14  
Because of its improved safety profile, UK became the preferred lytic agent until the 1980s, 
when recombinant t-PA (rt-PA) was brought onto the market15.  
 
Figure 2: Mechanism of action of SK and t-PA (used with permission from Dr R.E. Klabunde) 
First produced on a larger scale using DNA-technology at the start of the 1980s by Pennica and 
colleagues15, rt-PA has since been in common use for the treatment of myocardial infarction, 
stroke, lower extremity ischaemia and deep venous thromboembolism.  
Naturally occurring t-PA is a single-chain serine protease that is converted by plasmin to a two-
chain form. Both the single and the two-chain forms have enzymatic activity and rt-PA is a 
combination of the two forms, although the single-chain forms dominates.15 The half-life of rt-
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PA in plasma is five minutes.16 Compared with SK, rt-PA has been shown to reduce overall 
mortality in AMI, although at a slightly increased risk of intracranial haemorrhage.17 It has been 
used extensively in several different clinical settings and is currently the only agent approved for 
use in acute ischaemic stroke.16 Figure 2 shows a graphical representation of the mechanism of 
action of SK and rt-PA.  
 
Further advances have been made to identify thrombolytic agents that potentially carry a 
reduced risk of unwanted side-effects.18 An ideal thrombolytic agent would be one that provides 
quick and efficient clot lysis at the site of the thrombus or embolus but does not induce systemic 
fibrinolysis, reducing the risk of bleeding at remote sites.19                
Newer developments include tenecteplase (TNK-t-PA), which is a mutated version of t-PA with 
substitutions at three sites of the original amino acid sequence. These substitutions reduce 
metabolism in the liver and cause an increased resistance to inactivation by circulating PAI-1, 
thereby increasing plasma half-life as well as increasing fibrin specificity (in theory reducing 
non-specific plasmin activation).20 Tenecteplase has mainly been used in the setting of AMI20, 
but also in the treatment of acute lower limb ischaemia.21 
Reteplase is another bioengineered variety of t-PA where some of the domains of the original 
structure have been deleted, which has resulted in reduced fibrin binding and a longer half-life 
(14-18 minutes compared with 4-5 minutes for rt-PA). Like tenecteplase, reteplase has mainly 
been used in AMI, where it has been studied in e.g. the GUSTO III22 and the INJECT22 trials. 
These trials failed to show a reduction in AMI-related mortality for reteplase, but the INJECT 
study showed a reduction in morbidity compared with those receiving rt-PA.  
Another novel fibrinolytic is pro-urokinase. This is a precursor to UK that binds to fibrin. On 
binding to fibrin, the single-chain molecule of pro-UK is cleaved into the two-chain 
configuration of full molecular weight UK, which enhances its activity up to 1,000-fold.23 Pro-
UK shows an increased fibrin specificity compared with UK. It has been used in AMI24 and for 
treating lower limb ischaemia in the PURPOSE trial.25  
There has also been development of direct-acting plasmin activators, i.e. substances that do not 
require the activation of plasminogen.  
 
Alfimeprase is a recombinant derivative of fibrolase, a metalloproteinase found in southern 
copperhead snake venom. This enzyme directly cleaves the Aα chain of fibrinogen without the 
need for activation of the endogenous fibrinolytic system.26 This leads to a quicker onset of 
action of thrombolysis. Alfimeprase is inactivated by α2-macroglobulin, an endogenous 
inhibitor of metalloproteinases.26 This inhibition is rapid and theoretically reduces the risk of 
remote-site bleeding. However, it makes catheter-based delivery of alfimeprase directly into the 
thrombus necessary, as systemic administration would lead to its immediate degradation.  
Clinically, alfimeprase has been used most recently in a controlled trial by Han and colleagues 
comparing alfimeprase and placebo for CDT of acute lower limb ischaemia.27 However, this 
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trial failed to show any benefit in terms of avoidance of subsequent open surgery compared with 
placebo.  
 
Plasmin itself has also been investigated as a possible thrombolytic. In the setting of systemic 
thrombolysis, direct administration of plasmin would be unfeasible because of its rapid 
degradation by α2-antiplasmin in the circulation. However, like alfimeprase, intra-thrombus 
delivery (as used in CDT) would theoretically be possible, and the method is currently being 
evaluated in the PRIORITY trial for treating patients with peripheral arterial thrombosis.28 
 
Table 1: Common fibrinolytic agents in clinical use 
 
 Origin Indications Half-life (min) 
rt-PTA Recombinant Stroke, AMI, Peripheral arterial 
occlusion, DVT, pulmonary embolism 
5 
SK Streptococcus AMI, peripheral arterial occlusion, DVT, 
pulmonary embolism 
20 
UK* Cell culture AMI, pulmonary embolism, DVT, 
peripheral arterial occlusion 
15 
Reteplase Recombinant AMI, peripheral arterial occlusion 15 
TNK-t-PA Recombinant AMI 15 
*Not currently available  
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1.3 THROMBOLYSIS IN PRACTICE – APPLICATIONS, OUTCOMES AND 
COMPLICATIONS  
 
1.3.1 Acute limb ischaemia  
 
Since the study by Dotter and colleagues in 19742, in which low-dose streptokinase was 
administered for the first time directly into the target vessel using a catheter-directed approach in 
patients with acute lower extremity ischaemia, CDT has become widely used in the treatment of 
this very large group of patients. The selective delivery of the thrombolytic agent into the 
thrombus itself or the immediate surrounding area decreases the degree of systemic 
fibrinolysis29, and the method is readily combined with other endovascular techniques in order to 
e.g. correct any underlying culprit lesion, which provides a theoretical advantage over traditional 
open embolectomy or thrombectomy. However, due to its mechanism of action, the onset of 
lysis and thus time to reperfusion may be slower compared with open surgery, which limits its 
use to patients whose limbs are not immediately threatened.  
 
During the 1990s, Ouriel and colleagues performed three randomised, controlled trials (Ouriel 
199430, STILE14 and TOPAS31) with a total of 951 patients comparing open surgery with 
thrombolysis using either rt-PA or UK. Subgroup analyses were subsequently performed using 
data from the STILE-cohort, resulting in a further two publications reporting on outcomes in 
native vessels32 and bypass grafts.33  
 
In the STILE trial, the risk of death and amputation was similar for CDT compared with open 
surgery, although there was an increase in all-cause morbidity in those patients undergoing 
thrombolysis, which caused the trial to be stopped prematurely. Moreover, in a subgroup 
analysis of the data from this study, it was noted that occlusion of native arteries was associated 
with a higher risk of amputation for CDT compared with open surgery, whereas bypass graft 
occlusion of less than 14 days’ duration fared better after CDT than surgery.14 
In the TOPAS trial, there was no difference in overall and amputation-free survival between the 
CDT and the open surgery groups (68% amputation-free survival at one year).31  
 
In an updated Cochrane review, Berridge and colleagues34 examined the cumulative results of 
available randomised trials comparing thrombolysis with open surgery for the initial 
management of acute limb ischaemia. In this review, the above trials (STILE and TOPAS) were 
included together with a publication by Nilsson and co-workers35 in which the authors 
randomised 20 patients to either thrombolysis with rt-PA (n=11) or open surgery. In this study, 
there were no differences in death, amputation or stroke at 30 days, although the event rate was 
low with only one amputation and one death (both in the surgery group) and no events in the 
thrombolysis group.  
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In a pooled analysis of the randomised trials above, there was a significantly higher risk of 
bleeding (odds ratio 2.8; 95% CI 1.7-4.6), stroke (OR 6.41; 95% CI 1.57-26.22) and distal 
embolisation (OR 8.35; 95% CI 4.47-15.58) in the thrombolysis patients, although thrombolysis 
did reduce the level of surgery required at 30 days (OR 5.37; 95% CI 3.99-7.22). There were no 
significant differences in amputation-free survival or death at 30 days or one year. Based on the 
available evidence, the Cochrane review concluded that there is no evidence either to support or 
discourage the use of thrombolysis over open surgery for patients. 
 
It is important to note that the included studies were very heterogenous in terms of duration of 
ischaemia, thrombolysis protocols used (duration and type of thrombolytic agent) and also 
differed with regards to reporting standards. Furthermore, given that the most recent of the 
included trials was performed almost 10 years ago, it is unclear whether the results are directly 
applicable today, as there have since been technical advances made within the endovascular 
field.  
 
In a more recent study, Kuoppala and colleagues reported on 220 patients who had undergone 
thrombolysis for acute limb ischaemia. In this study, the amputation-free survival was in excess 
of 80% at one year with a frequency of bleeding complications of 33%, although only 6% of 
these patients required premature cessation of thrombolysis. In subsequent multivariate analyses 
of factors associated with amputation during follow-up, degree of lysis, severity of ischaemia 
(motor deficit and presence of ulcers) and ischaemic heart disease were found to be independent 
predictors of loss of limb.  
 
Thrombolysis has also been shown to be beneficial in the particular case of patients presenting 
with occlusion of a popliteal artery aneurysm, where use of the technique prior to arterial 
reconstruction led to an improvement of the distal run-off from the occluded aneurysm and 
thereby leg-salvage.36  
 
 
1.3.2 Thrombolysis for stroke 
 
The first large investigation of the use of thrombolysis for the treatment of acute stroke was the 
National Institute of Neurological Disorders trial (NINDS), which was published in 1995.37 This 
study was actually a joint report of two connected trials with a total of 624 included patients, and 
showed a significant improvement in disability (as measured by a reduction in the National 
Institutes of Health Stroke Stroke Scale (NIHSS)) for patients who were treated with intravenous 
(i.e. systemic) rt-PA within three hours after the onset of stroke symptoms. In the NINDS trial, 
the frequency of symptomatic intracerebral haemorrhage after thrombolysis was reported as 
6.4%. There have since been further large trials comparing rt-PA with placebo for the treatment 
of stroke, and in a meta-analysis of 6,756 patients38, rt-PA was shown to increase the chance of a 
reduction in disability compared with placebo for all time points up to 4.5 hours after the onset 
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of symptoms with a maximum benefit seen within three hours (OR 1.75; 95% CI 1.35-2.27) 
after onset of symptoms. A ‘good’ outcome was defined as an absence of significant disability at 
three or six months following the initial stroke, i.e. by a modified Rankin score of 0 to 1. There 
was a significantly increased risk of symptomatic intracranial haemorrhage following rt-PA 
compared with placebo with an O.R of 5.55 (95% CI 4.01-7.7) and of fatal intracranial 
haemorrhage (OR 7.14; 95% CI 3.14-12.58). However, there was no difference in mortality 
between the groups (hazard ratio 1.11; 95% CI 0.99-1.25). The compound conclusion drawn 
from this comprehensive analysis was that although rt-PA increases the risk of intracranial 
haemorrhage, this risk is offset by an increased likelihood of a good outcome after stroke if 
given within 4.5 hours after symptom onset, with benefits proportionally greater if treatment is 
given earlier.  
 
Based on the available evidence, thrombolysis has become widely used in the acute management 
of stroke, which naturally has led to a significant increase in the number of patients receiving 
this treatment. A review of data published by the Swedish Stroke Registry (Riks-Stroke) shows 
that the number of patients receiving cerebral reperfusion therapy (i.e. thrombolysis or catheter-
directed thrombectomy) has more than doubled since 2010 (5% in 2010 to over 12% in 2014).39 
In a study from 2009, Gladstone and colleagues40 noted that the number of patients presenting 
with either a transient ischaemic attack (TIA) or stroke who had a concomitant significant 
carotid artery stenosis (50-99% lumen reduction), and were therefore possible candidates for 
carotid intervention, was in the region of 10% (1011 of 10 213 patients).  
 
The number of patients receiving thrombolysis for stroke who then proceed to carotid surgery or 
stenting may therefore be expected to increase. However, prior thrombolytic therapy may bring 
an altered spectrum of complications to this patient group, in particular with regards to 
periprocedural stroke, intracranial haemorrhage and perioperative bleeding. There have been a 
few studies examining smaller cohorts of patients undergoing carotid endarterectomy (CEA) 
after thrombolysis for stroke, but none of these have conclusively demonstrated an increased risk 
of adverse events.41-44 A recent systematic review of a total of 114 patients who had undergone 
CEA or stenting after stroke thrombolysis showed similar rates of stroke and death within 30 
days compared with patients who had not undergone prior thrombolysis.45 
 
1.3.3 Thrombolysis for dialysis access thrombosis 
 
In 2011, there were more than two million patients undergoing haemodialysis treatment (HD) 
for end-stage renal failure (ESRF) worldwide.46 For these patients, a functioning vascular access 
is a necessity. A vascular access may be an autologous fistula (AVF; i.e. a non-anatomical 
arteriovenous connection between a native artery and a native vein), an arteriovenous graft 
(AVG; i.e. an arteriovenous connection using a synthetic conduit) or a central dialysis catheter. 
AVFs and AVGs are generally preferred over dialysis catheters, as they have been associated 
with improved patient survival and reduced morbidity.47 
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Dialysis access thrombosis is unfortunately a very common complication affecting both AVFs 
and AVGs, resulting in significant patient morbidity and healthcare-associated costs.48  
 
As with acute limb ischaemia, access thrombosis has traditionally been treated using open 
surgical thrombectomy for removal of the offending thrombus. However, this may lead to failure 
in treating any underlying culprit lesion not immediately obvious at the surgical site. Alternative 
endovascular strategies may therefore offer a treatment advantage, as they allow for a 
visualisation of access anatomy and the possibility to correct remote lesions during the same 
session.  
 
Thrombolysis for dialysis access thrombosis was first described in 198549, when Zeit and 
colleagues instilled SK solution through multiple needle puncture sites of thrombosed AVGs. In 
this early cohort, 73% of patients had successful recanalisation of their access, although 30% 
required subsequent corrective surgery. Thrombolysis has subsequently been used with 
increasing frequency, often in the form of the ‘lyse and wait’ technique introduced in 199750 in 
which the thrombolytic agent in a mix with heparin was instilled into the AVG during occlusion 
of the arterial and venous ends. However, there remains a relative paucity of evidence 
surrounding endovascular treatment of the thrombosed native fistula.  
 
In a report by Rajan and colleagues51, a 73% immediate success rate and an assisted primary 
patency of 43% at 43% at three months were achieved after bolus injection of UK or rt-PA. In a 
more recent series, it was noted that technical success following endovascular treatment was 
lower for AVFs than AVGs, with reported angiographic success-rates of 80.3% compared with 
93.7% for the grafts.52  
 
A meta-analysis of studies comparing outcomes after endovascular procedeures with open 
surgery for dialysis access thrombosis did not reveal any significant differences in technical 
success (OR 1.4; 95% CI 0.91-2.14), 30-day primary patency (OR 1.14; 95% CI 0.79-1.68), 
need for central dialysis catheter (OR 0.77; 95% CI 0.44-1.34) or morbidity (OR 1.12; 95% CI 
0.67-1.86). On the other hand, there was a trend towards an increase in 1-year patency for those 
having undergone open surgery (OR 2.08; 95% CI 0.97-4.45). However, the studies included in 
the meta-analysis employed a variety of techniques, such as pharmacomechanical thrombolysis 
(the use of a catheter device to fragment the thrombus; see below for further discussion), under 
the endovascular umbrella. The resulting heterogeneity limits the applicability of the findings.  
 
Factors that may affect the risk of reocclusion after surgery or endovascular treatment of access 
thrombosis were studied by Crikis and colleagues.53 These authors did not detect any difference 
in the risk of reocclusion after initial endovascular treatment for access thrombosis between 
AVFs and AVGs, although the risk of a second reocclusion was higher for AVGs compared 
with AVFs (rate ratio 0.3; 95% CI 0.11-0.8). In this study, a history of previous deep venous 
thrombosis (DVT) was also found to increase the risk of a second reocclusion (rate ratio 4.14; 
95% CI 1.3-13.09), whereas on-going anticoagulant treatment with either warfarin or heparin 
significantly lowered the risk (rate ratio 0.14; 95% CI 0.04-0.71).  
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1.3.4 Other frequently used applications of thrombolysis  
 
Deep venous thrombosis:  
Both systemic and catheter-directed thrombolysis have been used in the treatment of deep vein 
thrombosis (DVT). The aim of treatment is to reduce the risk of subsequent pulmonary 
embolism, induce venous recanalisation and reduce the risk of development of the post-
thrombotic syndrome, a state of chronic deep venous insufficiency that can cause leg swelling, 
oedema, venous eczema and ultimately venous ulceration. Compared with standard treatment 
with low-molecular weight heparin alone, thrombolysis more frequently results in venous 
patency (risk ratio 4.9; 95% CI 1.66-14.53) and reduced risk of the post-thrombotic syndrome 
(relative risk 0.64; 95% CI 0.52-0.79), but also an increased risk of peri-procedural bleeding 
(relative risk 2.23; 95% CI 1.51-3.52).54 Based on the available evidence, current guidelines for 
the treatment of DVT recommend CDT if the following criteria are met: symptoms of <14 days, 
good functional status, life-expectancy of more than one year and low risk of bleeding.55 
 
Pulmonary embolism:  
Systemic thrombolysis has been used in the treatment of pulmonary embolism (PE). In theory, 
thrombolysis offers enhanced clot lysis and a reduced time to pulmonary vascular patency. 
However, there is still uncertainty as to which patients benefit the most from such treatment. In a 
recent Cochrane review, currently available evidence (comprising 2,167 patients in the selected 
studies) was examined comparing thrombolysis with heparin alone.56 Compared with heparin, 
thrombolysis showed a reduction in all-cause mortality (odds ratio 0.57; 95% CI 0.37-0.87) and 
PE recurrence (OR 0.51; 95% CI 0.29-0.89), but a higher risk of bleeding (OR 2.9; 95% CI 
1.95-4.31 for major bleeding and OR 3.03; 95% CI 1-6-5.73 for minor bleeding).56  
 
There is currently no clear evidence to support the use of catheter-directed intervention as 
opposed to systemic thrombolysis, and there is no reported clinical trial comparing these 
strategies head-to-head.57 
 
Upper limb deep venous thrombosis:  
CDT has also been used in the setting of upper limb deep vein thrombosis. This is commonly 
seen in malignancy (more than 40% of patients with upper limb DVT are found to have some 
form of malignancy during subsequent investigations), in patients with indwelling central 
venous catheters and in patients with the thoracic outlet syndrome (TOS; a narrowing of the 
thoracic aperture causing extrinsic compression of the subclavian vein and/or artery).58 There is 
currently relatively limited evidence for the role of CDT in this patient group and no randomised 
studies comparing this treatment with heparin alone.59 In the case of TOS, patients are often 
treated with initial CDT to restore venous patency, after which surgical decompression of the 
thoracic outlet is undertaken.58 
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Central venous catheter occlusion:  
In addition to upper limb DVT, central venous catheter dysfunction may also be caused by the 
formation of a fibrin sheath that occludes the catheter tip. Semba and colleagues reported on two 
phase III trials, comprising 1,064 patients, of rt-PA for use in central venous catheter (CVC) 
thrombosis.60 In these studies, 2mg of rt-PA was instilled locally into the occluded CVC and left 
for 120 minutes. Success was achieved in 75% of patients after one dose of rt-PA, which rose to 
85% after two doses. There were no serious adverse outcomes such as intracranial haemorrhage 
or significant bleeding.  
 
 
1.3.5 Pharmacomechanical thrombolysis 
 
In addition to purely pharmacological thrombolysis via either the systemic or intra-arterial 
routes, several endovascular devices have been developed with the aim of providing quicker 
thrombus fragmentation and thereby quicker restoration of vessel patency. The use of such 
adjuncts may be referred to as pharmacomechanical thrombolysis (PMT). 
 
Please see Table 2 for a brief summary of the most common available devices.  
 
Table 2: Common pharmacomechanical thrombectomy devices 
 
 
Device Mechanism of action Applications 
Arrow Trerotola Rotational – metal basket at tip of 
catheter for fragmentation of 
thrombus 
Dialysis access thrombosis, 
pulmonary embolism  
Amplatz 
thrombectomy device 
Rotational – impeller at tip of 
catheter rotates rapidly pulling 
thrombus towards tip, causing 
fragmentation 
Dialysis access thrombosis 
Rotarex®  Rotational – spiral at tip of catheter 
‘drills’ into thrombus, central 
vacuum at tip draws thrombus into 
catheter where it is removed  
Peripheral arterial thrombosis, 
DVT, dialysis access 
thrombosis 
Trellis®  Oscillating wire between two 
balloons for thrombus 
fragmentation plus infusion of 
thrombolytic in treated segment 
DVT, peripheral arterial 
thrombosis 
AngioJet® Rheolytic – high-speed saline jets 
from tip of catheter create pressure 
gradient leading to fragmentation 
and evacuation of thrombus 
DVT, peripheral arterial 
thrombosis, PE, dialysis 
access thrombosis 
EKOS® Emission of ultrasonic waves thins 
fibrin component and enhances 
transportation of fibrinolytics into 
the target thrombus 
DVT 
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All the above devices carry a theoretical risk of vascular endothelial injury secondary to the 
trauma induced by the device, as well as a risk of haemolysis.61 The AngioJet® device has also 
been associated with the development of bradyarrhythmias, especially if the device is used close 
to the heart.62 The exact mechanism of this has not been elucidated, but is thought to involve the 
Bezold-Jarisch reflex63, a vagally mediated response to certain chemical stimuli within the 
heart.64  
 
There have so far been few randomised trials comparing PMT with CDT, especially in the 
setting of lower limb ischaemia.  
 
In the case of dialysis access thrombosis, Uflacker and colleagues compared the outcomes of 
PMT using the Amplatz device with surgical thrombectomy but did not detect any significant 
differences in immediate success (thrombus clearance and ability to dialyse using the access) or 
patency at 30 and 90 days post-procedure between the groups.65 In another study, the AngioJet® 
device was compared with open thrombectomy for thrombosis of prosthetic dialysis grafts. 
There was no difference in immediate success between open surgery or PMT, but there was a 
trend toward better patency in the open surgery group at both one and three months (41% versus 
31% at one month and 26% versus 15% at three months).  
 
In the setting of acute limb ischaemia, Byrne and co-workers conducted a retrospective review 
of 154 patients having either undergone CDT or PMT using the AngioJet® device for the 
treatment of acute limb ischaemia.66 In this study, there were no significant differences in overall 
primary patency, limb loss or complications between CDT and PMT, although PMT was 
associated with increased technical success rates compared with CDT (90.1% versus 78.3%; 
P=0.047).  
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1.4 TECHNICAL AND PRACTICAL ASPECTS OF THROMBOLYSIS 
 
1.4.1 Patient selection 
 
Careful patient selection is essential in order to minimise the risks of complications during 
systemic and catheter-directed thrombolysis. Moreover, the timing of treatment is important to 
ensure maximum benefit of treatment. In the setting of acute stroke, the American Heart 
Association and American Stroke Association (AHA/ASA) have produced joint guidelines to 
support clinical decision-making surrounding thrombolytic therapy.67 The indications and 
contraindications for intravenous thrombolysis for stroke are summarised in Table 3 below.  
 
 
 Table 3: Indications and contraindications for thrombolysis in acute ischaemic stroke.67 
Indications Contraindications 
Ischaemic stroke causing measurable 
neurological deficit 
Head trauma < 3 months prior 
Neurological signs not minor/isolated 
and not clearing spontaneously 
Myocardial infarction < 3 months prior 
No symptoms suggestive of 
subarachnoid haemorrhage 
Gastrointestinal/genitourinary bleeding within 3 weeks 
Onset of symptoms less than 3 hours 
prior 
Major surgery < 14 days prior 
 Non-compressible arterial puncture <7 days 
INR >1.7 and/or normal activated prothrombin time 
Recent trauma with active bleeding 
Platelet count <100x109/L 
Recent seizure with postictal impairment 
Multilobar infarction on CT 
Blood glucose <2.8mmol/L or >22 mmol/L 
 Pregnancy 
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In the setting of CDT for peripheral arterial occlusions, Table 4 outlines contraindications for 
treatment.  
 
Table 4: Absolute and relative contraindications for catheter-directed thrombolysis  
 
 
In addition to the above, in order to be eligible for CDT patients must be able to undergo 
endovascular treatment and to follow instructions by medical and nursing staff such that safe 
siting of an indwelling intra-arterial catheter for the duration of treatment can be achieved.  
 
1.4.2 Administration of the thrombolytic agent 
 
For intra-arterial CDT, thrombolysis is performed via an indwelling catheter with multiple side-
holes through which the thrombolytic agent is infused into the target vessel. In the case of lower 
limb ischaemia, vascular access is established through either an ante- or retrograde approach to 
the common femoral artery, often using ultrasound-guided micro-puncture. A vascular sheath is 
placed, through which the thrombolysis catheter is advanced over a guide-wire under 
fluoroscopic guidance. The aim is to place the tip of the catheter into the thrombus itself, or if it 
is not possible to pass the occlusion with the guide-wire, the catheter is placed as close to the 
thrombus as possible. The infusion of thrombolytic agent is then started, with or without a 
preceding bolus. In the case of rt-PA, a solution of drug diluted to 0.1mg/ml is often used and 
infused at rates of 0.5-1mg/h (i.e. 5-10ml/h). Control angiograms are then undertaken at varying 
frequencies depending on local guidelines and the clinical setting. Clot lysis is commonly seen 
after six to 24 hours. During the infusion, low-molecular weight heparin (LMWH) is often given 
at regular intervals to prevent sheath thrombosis. Alternatively, a continuous infusion of 
Absolute Relative 
Active/ongoing bleeding Cardiopulmonary resuscitation within 10 days 
Gastrointestinal bleeding <10 days Major surgery/trauma <10 days 
Stroke/TIA <2 months Systolic blood pressure >180mmHg or 
diastolic >110mmHg 
Neurosurgery or intracranial trauma < 3 
months 
Intracranial tumour or arteriovenous 
malformation 
 Severe limb ischaemia with motor and sensory 
deficit 
 Recent eye surgery 
Diabetic haemorrhagic retinopathy 
Hepatic failure 
Bacterial endocarditis 
Pregnancy 
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unfractionated heparin (UFH) adjusted to activated partial thromboplastin time (APTT) may be 
used.  
 
A similar protocol is used for dialysis access thrombolysis, although here two catheters may be 
placed in crossing directions in order to deliver the thrombolytic agent to both the arterial and 
venous limbs of the AVF/AVG.  
 
Patients undergoing CDT are commonly cared for in an intensive or intermediate care setting for 
continuous monitoring of haemodynamic parameters, development of complications (e.g. 
bleeding) and limb status (in the case of acute limb ischaemia). In some vascular centres, 
patients undergo observation on a general surgical/vascular ward during CDT. It is unclear 
whether this confers a greater risk of complications and adverse events compared with a high-
dependency setting. 
 
In the treatment of acute ischaemic stroke, the currently used protocol involves the intravenous 
administration of rt-PA in a dose of 0.9mg/kg, 10% of which is administered as a bolus over one 
to two minutes followed by the remaining 90% as an infusion over 60 minutes.68 Patients should 
preferably be treated at an institution with a stroke centre or if not, an rt-PA infusion may be 
started at the receiving hospital while awaiting transfer to a stroke centre.  
 
1.4.3 Monitoring of thrombolytic therapy 
 
Currently, there is no specific laboratory test to assess the efficacy of thrombolysis69, although 
there are tests that will indicate the function of the various components of the coagulation 
system, as well as assays for assessing the degree of systemic fibrinolysis. During intra-arterial 
CDT, measurement of fibrinogen levels are undertaken in most centres to assess fibrinolysis, 
and the thrombolytic infusion may be stopped if the fibrinogen level falls below 1g/L or if there 
is an obvious trend of falling levels. The Clauss method is most commonly used in clinical 
settings.70  
 
In addition, coagulation is monitored by measuring the prothrombin time (PT), which is an 
indicator of the function of the tissue factor pathway (factors V, VII, X and fibrinogen), and the 
activated partial thromboplastin time (APTT), which assesses both the contact activation (factors 
XII, XI and prekallikrein) and common pathways of the coagulation cascade.71  
 
More recently, there have been investigations into the role of viscoelastic methods, such as 
thromboelastography (TEG) and rotational thromboelastometry (ROTEM), in the setting of 
thrombolysis and also trauma. These methods provide a measurement of clot formation, strength 
and fibrinolysis.72 However, they are not yet used on a larger scale for the routine monitoring of 
patients undergoing thrombolysis.  
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis was to examine the role, outcomes and safety of thrombolysis in 
the setting of vascular surgery. More specifically, the aims were: 
I. To assess the clinical outcomes after thrombolysis in patients with lower limb ischaemia 
secondary to the occlusion of an infrainguinal bypass graft 
II. To evaluate the safety of early carotid endarterectomy and carotid artery stenting in patients 
who had undergone systemic thrombolysis for stroke 
III. To compare the clinical outcomes of thrombolysis with those of open surgical thrombectomy 
in patients with thrombosis of native and prosthetic dialysis accesses 
IV. To investigate the role of the level of care in patient safety during intra-arterial thrombolysis  
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3 PATIENTS AND METHODS 
 
3.1 STUDY DESIGN AND STUDY POPULATIONS 
Patients were identified through local databases of radiological and surgical procedures at the 
participating hospitals (Studies I, III, IV) based on codes for the interventional procedures 
performed during the study time periods.  
For Study II, the Swedish Vascular registry (Swedvasc) was used in conjunction with the 
Swedish Stroke registry (Riks-Stroke) for identification of the patients during the study time 
period. Please see Table 5 for an overview of the study designs and patient populations.  
Table 5: Study designs and patient populations in the constituent studies 
 Patients and study period Design and methods Centres 
Study I All patients (n=123) undergoing 
CDT for infrainguinal bypass 
graft occlusion 2000-2008 
Retrospective cohort study 
of treatment outcomes and 
risk factors for technical 
failure, amputation and 
mortality 
Karolinska 
University 
Hospital and 
Skåne 
University 
Hospital 
Study II Patients undergoing carotid 
endarterectomy or stenting 2008-
2012 with (n=79) or without 
(n=3919) preceding thrombolysis 
for stroke 
Retrospective analysis of 
prospective data collected 
from Swedvasc, Riks-Stroke 
and individual patient 
records. The influence of 
thrombolysis on outcomes 
was assessed  
Nationwide 
(Sweden) 
Study 
III 
All patients (n=131) undergoing 
CDT or open thrombectomy for 
primary dialysis access 
thrombosis 2005-2013 
Retrospective cohort study 
with regard to outcomes after 
open or endovascular 
treatment  
Karolinska 
University 
Hospital and 
South 
General 
Hospital 
Study 
IV 
All patients (n=252) undergoing 
CDT for limb ischaemia or 
dialysis access thrombosis 
between 2005-2013 
Retrospective cohort study 
of safety-outcomes of two 
different care regimes during 
CDT and risk factors for 
patient transfer to a higher 
level of care 
Karolinska 
University 
Hospital and 
South 
General 
Hospital 
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3.2 ETHICAL CONSIDERATIONS 
 
3.2.1 Study I  
Study I was a quality audit of the outcomes of thrombolysis for the treatment of patients with 
occlusion of an infrainguinal bypass graft. Patients had already been treated using standard 
protocols and there was no effect on patient care and follow-up. Patients had been treated either 
at Karolinska University Hospital in Stockholm, Sweden or Skåne University Hospital in 
Malmö, Sweden. The Malmö cohort was a subgroup of patients already used in a larger 
prospective analysis of infrainguinal thrombolysis for which ethical approval had already been 
granted. The regional ethics board in Lund, Sweden had no reservations concerning study design 
and data collection. This, together with the permission from the local Head of Department to 
conduct a quality assurance audit, was considered adequate with regards to ethical analysis.  
3.2.2 Studies II-IV 
These studies were granted ethical permission from the regional ethics committee in Stockholm. 
As above, patients had already been treated using standard protocols and none of the studies 
influenced the follow-up of any of the patients. All data was collected from medical records, 
digital radiological databases (PACS-systems) and national quality registries (Study II). For 
Study II, written informed consent for accessing individual medical records was sought from 
patients or relatives (if patients were unable to give consent themselves). No such consent was 
deemed necessary by the ethics committee for Studies III and IV.  
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3.3  PATIENTS AND METHODS STUDY I 
 
The aim of this study was to assess the outcomes of catheter-directed thrombolysis in patients 
with thrombosis of an infrainguinal bypass graft and to examine any risk factors for adverse 
outcomes (technical failure, amputation and death).  
Study population 
The cohort consisted of all patients (n=123) who had been treated with CDT for infrainguinal 
bypass graft occlusion at Skåne University Hospital in Malmö and at Karolinska University 
Hospital in Stockholm. These two hospitals are tertiary referral centres for vascular and 
endovascular surgery, and have a combined catchment area of approximately 1.8 million people. 
The respective hospital database of radiological procedures was used to identify the patients. 
The study period was January 1, 2000 (Karolinska) and January 1, 2001 (Malmö) to December 
31, 2008.  
Study intervention 
All patients underwent CDT according to the protocol of the treating hospital. Briefly, patients 
were screened for the presence of any contra-indication, after which blood tests for clotting 
function were taken. Any previously performed imaging (computer tomography, duplex 
ultrasound, magnetic resonance imaging) was scrutinised before commencement of 
thrombolysis. Arterial access was established in the ipsi- or contralateral common femoral 
artery. A guide-wire was then used to pass the thrombus, whereafter a thrombolysis catheter 
with multiple side-holes was placed inside the thrombus. An infusion of rt-PA (Actilyse, 
Boehringer-Ingelheim) was then commenced at a rate of 1-2mg/h. Patients received either 
LMWH (Karolinska) or continuous UFH (Malmö) during thrombolysis to prevent sheath 
thrombosis. Control angiograms were performed at regular intervals depending on the clinical 
and radiological picture. Fibrinogen, PT and APTT were monitored at regular intervals 
according to local protocol.  
 
Data collection and outcome measures 
A retrospective review of the medical records of the included patients was conducted, which 
also included scrutiny of the radiological data from the endovascular procedures performed as 
part of the treatment. Mortality data was accessed via the patient records, which were linked to 
the Swedish Population Registry. Table 6 summarises the variables and their definitions. 
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Table 6: Variables and their definitions 
Variable Definition 
Hypertension  Systolic blood pressure >140mmHg or diastolic 
BP or >90mmHg or documented prescription of 
antihypertensive medication 
Cerebrovascular disease  Previous documented history of either a 
manifest stroke or transient ischaemic attack 
(TIA) 
Ischaemic heart disease  Previous history of myocardial infarction, 
angina pectoris, coronary artery bypass grafting 
or percutaneous coronary intervention 
DM  Documented DM treated either by diet, oral 
hypoglycaemic agents or insulin 
Atrial fibrillation History of atrial fibrillation 
Acute critical ischaemia of the lower 
limb  
Sudden impairment in limb perfusion causing a 
threat to tissue viability 
Technical failure  Insufficient degree of lysis – either no lysis or 
lysis without run-off on completion angiogram 
Additional interventions  Endovascular, open or combined (hybrid) 
procedures undertaken during the same 
inpatient episode 
Major amputation  Amputation above the level of the 
tarsometatarsal joint 
Major haemorrhage  Bleeding requiring surgical intervention or 
blood transfusion or cessation of thrombolysis 
 
 
Statistical analysis 
Statistical analysis was undertaken using IBM SPSS version 18. Continuous variables were 
expressed as mean ± standard deviation. Univariate analyses were undertaken using Pearson’s 
X2, Fisher’s exact test, Cramer’s V and Kendall’s Tau. Logistic regression was undertaken to 
identify variables associated with technical failure (a binary variable), and Cox regression was 
used to examine predictors of amputation and death. Survival analysis (amputation-free survival 
and patient survival) was performed using the Kaplan-Meier estimator.  
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3.4 PATIENTS AND METHODS STUDY II 
 
The aim of this study was to asses whether prior systemic thrombolysis for stroke affects the 
outcomes in patients subsequently undergoing carotid endarterectomy (CEA) or carotid artery 
stenting (CAS) for symptomatic carotid artery stenosis. The study consisted of patients from all 
vascular centres in Sweden where CEA and/or CAS are performed (n=22).  
Study population 
The study included all patients who had undergone CEA (n=71) or CAS (n=6) during the study 
period from May 1, 2008 to December 11, 2012 (n=3,998). Please see Figure 3 for a flow-chart 
of the study population.  
 
 
                Figure 3: Flow chart of patients included in study IV 
Study interventions 
Carotid endarterectomy 
Open surgery was performed under general or local anaesthesia depending on local protocol. 
Shunt use was left to the discretion of the operating surgeon. In some centres, eversion 
endarterectomy was performed, although the majority of centres performed a standard patch 
procedure.  
 
Carotid artery stenting 
CAS was undertaken under local anaesthesia. All centres used cerebral embolic protection (filter 
or flow-reversal).  
 
  
 
Symptomatic 
CEA/CAS patients 
2008-2012 
 n= 3998 
Thrombolysis first 
 n=79 
CEA  
n=71 
CAS 
n= 6 
No thrombolysis 
n=3919 
Swedvasc 
Riks-­‐Stroke 
Medical	  
records 
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Data collection and outcome measures 
Data from the Swedish Vascular registry and the Swedish Stroke registry was collected 
prospectively and analysed retrospectively in the study. Medical records were then double-
checked to ensure completeness of data and to collect information on variables that were not 
available in any of the registries (type of anaesthesia, use of intraoperative anticoagulation). 
Please see Table 7 for a summary of which data was collected from which source.  
 
It should be noted that 19 patients withheld their consent for scrutiny of their medical records, 
which resulted in incompleteness of data concerning comorbidities.  
 
 
Table 7: Summary of data collection Study II 
 
 Swedvasc Riks-
Stroke 
Medical 
records 
Age, sex X   
Comorbidities X X X 
Medications  X X 
Index symptoms X  X 
Initial cerebral imaging  X X 
Neurological disability (modified 
Rankin score and NIHSS) 
 X X 
Degree of carotid stenosis X  X 
Type of carotid procedure X   
Intraoperative details (type of 
anaesthesia, use of shunt, 
intraoperative anticoagulation) 
X  X 
Complications after CEA/CAS  X  X 
30-day follow-up X  X 
 
 
Statistical analysis 
All data was analysed using IBM SPSS version 21 with the addition of the online interface at 
http://www.quantpsy.org/fisher/fisher.htm for the calculation of Fisher’s exact test. Descriptive 
statistics were calculated as appropriate and P-values <0.05 were considered statistically 
significant.  
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3.5 PATIENTS AND METHODS STUDY III 
 
The purpose of this study was to compare the outcome of an endovascular approach with 
pharmacological thrombolysis with open surgery for the treatment of a first episode of dialysis 
access thrombosis. A secondary aim was to identify any factors associated with the risk of re-
thrombosis following the initial procedure.  
 
Study population 
The study included all patients (n=131) presenting to Karolinska University Hospital and South 
General Hospital for a first episode (for the access in question) of dialysis access thrombosis 
between December 1, 2005, and December 31, 2013. Figure 4 shows the distribution of the 
study interventions.  
 
Figure 4: Distribution of the study interventions 
 
Study interventions 
Patients underwent either pharmacological thrombolysis with indwelling catheter(s) or open 
surgery with Fogarty balloon thrombectomy. Patients undergoing pharmacomechanical 
thrombolysis without continuous infusion of rt-PA were excluded from the study. There was no 
formal treatment algorithm for the choice of endovascular or open treatment, and the decision 
regarding treatment type was left to the physician in charge. 
 
Data collection and outcome measures 
Data was collected retrospectively from patient medical records concerning comorbidities, 
aetiology of renal disease, concomitant antithrombotic medication and adjunctive procedures 
(any open or endovascular procedure undertaken as a complement to the index procedure during 
the same inpatient episode).  
 
Patients were divided into four groups based on treatment (thrombolysis versus surgery), access 
anatomy and type (AVF versus AVG): (1) AVF thrombolysis, (2) AVF thrombectomy, (3) AVG 
thrombolysis and (4) AVG thrombectomy.  
149	  episodes	  of	  primary	  access	  
thrombosis	  in	  131	  pa6ents	  
Surgical	  thrombectomy	  
(n=107)	  in	  90	  pa6ents 
Catheter-­‐directed	  thrombolysis	  
(n=42)	  in	  41	  pa6ents 
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Patency was calculated as the time from either thrombolysis or thrombectomy and the next 
clinically verified access rethrombosis (if any). This was therefore the post-intervention assisted 
primary patency.73  
 
Technical success was defined as at least one successful dialysis session (using the access in 
question) after the procedure.  
 
Statistical analysis 
Baseline demographic data was analysed using IBM SPSS version 21. Stata release 13 was used 
for all other analyses. 
 
Patency time was calculated using the Kaplan-Meier method, and Cox regression was used to 
calculate crude and adjusted hazard ratios. Poisson regression was used to model the risk of 
rethrombosis over time for each of the four treatment groups.  
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3.6 PATIENTS AND METHODS STUDY IV 
 
The aim of this study was to investigate whether the level of care influences the safety of 
catheter-directed intra-arterial thrombolysis. Traditionally, patients undergoing CDT have been 
cared for on a high-dependency ward with continuous monitoring of haemodynamic parameters 
for the early detection of complications such as bleeding. However, it is unknown whether care 
on a general ward offering a lower level of care is associated with an increase in adverse safety 
outcomes. 
 
Study population 
All patients (n=252) undergoing CDT for limb ischaemia or dialysis access thrombosis at 
Karolinska University Hospital  (Centre 1) and South General Hospital (Centre 2) between 
January 1, 2012 and December 31, 2014 were included.  
 
Study intervention 
CDT was performed as described in Study I and III, and there was no difference in technical 
protocols between the hospitals. Patients at Centre 1 were cared for on a general vascular ward 
with standard nursing care and without invasive haemodynamic monitoring, whereas patients at 
Centre 2 were kept on the postoperative recovery unit where haemodynamic parameters (arterial 
blood pressure, ECG and pulse-oximetry) were continuously monitored and there was a 
decreased ratio of patients to nursing staff.  
 
Data collection and outcome measures 
In addition to baseline demographic variables, data was also collected regarding antithrombotic 
medication, bleeding and non bleeding-related complications, site of thrombolysis catheter (arm, 
groin, dialysis access), clinical success (angiographic and clinical evidence of improvement in 
vascular patency) and any conversion to open surgery or amputation during the same inpatient 
episode. Please see Table 8 for a list of the complication-related variables and classification of 
bleeding used.  
 
Statistics 
All analyses were conducted using IBM SPSS version 23. Continuous variables were expressed 
as median and range unless otherwise specified. Univariate analyses of binary and nominal 
variables were conducted using cross-tabulations (values reported to Pearson’s X2 and Fisher’s 
exact test). Variables associated with bleeding, non-bleeding complications and transfer to a 
higher level of care were entered into a logistic regression model with forced entry of the 
variables. Significant associations were expressed as odds ratios with 95% confidence intervals. 
Statistical significance was considered for P-values of less than .05.  
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       Table 8: Variables relating to outcomes Study IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *Bleeding was defined according to Mehran 2011.74  
§ Grade 4 (bleeding associated with coronary artery bypass grafting) was not applicable to this study. 
 
 
  
Variable Definition 
Acute myocardial 
infarction 
Clinical signs consistent with the diagnosis and 
elevation of serum cardiac enzymes 
Ischaemic stroke Clinical signs consistent with the diagnosis and 
absence of intracerebral bleed on computed 
tomography 
Haemorrhagic stroke Clinical signs consistent with the diagnosis and 
radiological evidence of intracranial bleeding 
Intractable pain Pain not responding to treatment with standard doses 
of opiate and non-opiate analgesics, or requiring 
larger than expected analgesic doses 
Confusion Confusion or delirium severe enough to necessitate 
cessation of CDT or moving the patient to a higher 
level of care 
Bleeding*           Grade 0 No evidence of bleeding 
                           Grade 1 Minor bleeding not requiring intervention 
                           Grade 2 Moderate bleeding requiring some form of 
intervention, e.g. compression, cessation of 
thrombolysis 
 Grade 3a Any transfusion with overt bleeding or overt bleeding 
with a drop in haemoglobin ≥3 to <5g/dL 
Grade 3b 
Overt bleeding and haemoglobin drop <5g/dL or 
cardiac tamponade or bleeding requiring surgical 
intervention for control or bleeding requiring 
intravenous vasoactive drugs  
 
Grade5§ Fatal bleeding 
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4 RESULTS AND DISCUSSION 
 
 
4.1 RESULTS AND DISCUSSION STUDY I 
 
Study I examined the outcomes of catheter-directed thrombolysis for the treatment of native and 
prosthetic bypass graft occlusion. 
 
Patient characteristics and clinical findings preceding thrombolysis 
During the study period, there were in total 659 inpatient episodes for intra-arterial thrombolysis 
at the participating centres of which 123 were due to infra-inguinal bypass graft occlusion. A 
summary of patient characteristics can be found in the left hand column of Table 9 below.  
 
Table 9: Patient characteristics and factors associated with adverse outcome and technical              
 failure Study I 
 
 
 
 
 
 Patients 
(%) 
Technical failure 
(%) 
Major amputation 
(%) 
Mortality 
(%) 
Major 
amputation or 
mortality (%) 
      
All 123 18 (15) 34/122 (28) 57 (46) 65 (53) 
      
Women 47 (38) 7 (15) 16/46 (35) 25 (53) 29 (62) 
Age ≥  80 years 26 (21) 4/26 (15) 8/25 (32) 19/26 
(73)(p=0.002) 
19/26 
(73)(p=0.02) 
Smoking 86/107 (80) 14 (16) 25 (29) 43 (50)(p=0.077) 48 (56) 
Hypertension 88/122 (72) 14 (16) 27/87 (31) 48 (55)(p=0.005) 53 (60)(p=0.013) 
Diabetes Mellitus 33 (27) 7 (21) 11 (33) 17 (52) 19 (58) 
Ischemic heart disease 53/122 (43) 3 (6)(p=0.013) 14/52 (27) 28 (53) 30 (57) 
Cerebrovascular 
disease 
21/122 (17) 1 (5) 5/20 (25) 13/21 (62) 14/21 (67) 
Atrial fibrillation 27/122 (22) 3 (11) 6/26 (23) 16/27 (59) 16/27 (59) 
      
Medication      
Platelet aggregation 
inhibitor 
87/119 (73) 14 (16) 23/86 (27) 39 (45) 46 (53) 
Warfarin 26/119 (22) 3 (12) 9 (35) 11 (42) 12 (46) 
      
Disease specifics      
Acute lower limb 
ischemia 
88/119 (74) 12 (14) 26/87 (30) 47 (53)(p=0.008) 51 (58)(p=0.065) 
Synthetic graft 
occlusion 
82/122 (67) 9 (11)(p=0.092) 27 (33)(p=0.043) 39 (48) 46 (56) 
Supra-inguinal 
proximal  
anastomosis 
26/121 (21) 2 (8) 8 (31) 9 (35) 12 (46) 
Graft stenosis, any 49/121 (4) 7 (14) 14 (29) 21 (43) 25 (51) 
Adjunctive 
intervention 
87/121 (72) 14 (16) 20/86 (23)(p=0.098) 40 (46) 45 (52) 
      
Outcome      
Major haemorrhage 16/121 (13) 3 (19) 6 (38) 11 (69)(p=0.053) 12 (75)(p=0.057) 
Technical failure 18/123 (15) - 8 (44)(p=0.089) 10 (56) 11 (61) 
Major amputation 34/122 (28) - - 27 (79)(p<0.001) - 
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Nineteen patients (15.4%) underwent thrombolysis of their bypass graft more than once. 
Seventy-four per cent (89/120) of patients presented with acute critical limb ischaemia, 24% 
(29/120) had new-onset claudication. Only two patients were asymptomatic.  
 
Bypass graft characteristics 
Please see Table 10 for a summary of the frequencies of different types of bypass grafts in the 
cohort. The median time between bypass graft placement and subsequent occlusion was 39.5 
months (range 0.5-507 months). Sixty-seven per cent of grafts were synthetic 
(polytetrafluororethylene, Dacron or composite).  
 
Table 10: Graft anatomy and material* 
Bypass graft anatomy Patients (%) Vein: synthetic 
Aortobifemoral bypass 25(21) 0:25 
Femoro-femoral cross-over 9 (7) 0:9 
Femoropopliteal bypass 
above-knee 
25 (21) 4:21 
Femoropopliteal bypass 
below-knee 
27 (22) 13:14 
Femorodistal bypass 29 (24) 23:6 
Two bypass grafts 6 (4) 0:6 
*In two cases, it was not possible to ascertain graft anatomy. 
 
Angiographic findings and adjunctive interventions 
The median duration of thrombolysis was 19 hours (range one to 51 hours). Graft-related lesions 
such as graft stenosis or kinking were the most common finding at angiography (43%). The next 
most common finding was stenoses of the native recipient artery (27%). However, almost a 
quarter (23%) of patients had no discernible culprit lesion. Twenty-five (21%) patients had more 
than one angiographic lesion.Adjunctive interventions were undertaken in 86 patients (70%) of 
cases and of these, 47 underwent an endovascular procedure, 26 underwent open surgery and 13 
underwent a hybrid (i.e. simultaneous open and endovascular) procedure.  
 
Complications 
Major haemorrhage occurred in 16 patients (13.2%), but this was not associated with the total 
administered dose of rt-PA, patient age or graft material (P=0.21, 0.52 and 0.19 respectively). 
There were two haemorrhagic strokes (1.6%) and three fatal myocardial infarctions (2.4%).  
 
Factors associated with major adverse outcome and technical failure 
Technical failure of thrombolysis occurred in 18 patients (15%). Older grafts had a higher 
likelihood of technical success, with a median graft age of 45 months (range 0.5 to 507 months) 
for those with successful thrombolysis compared with 10 months (range one to 120 months) for 
those with technical failure; P=0.014). Patients with ischaemic heart disease exhibited a lesser 
rate of technical failure (P=0.013). In a binary logistic regression model with heart disease, graft 
age and material as covariates, heart disease remained as an independent factor associated with 
technical success (O.R 4, 95% CI 1.1-15.1; P=0.04). Patients with heart disease were not treated 
more often with any antithrombotic medication compared with the remaining cohort (P=0.51).  
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The 30-day amputation rate was 11.4% (14/123), and at one year this had risen to 25.4% 
(31/122). Technical failure was strongly correlated with amputation at 30 days (P=0-001, 
r=0.29). Age and synthetic graft material were both associated with amputation during follow-up 
(P=0.008 and 0.043 respectively). When technical failure, patient age, graft material and 
adjunctive intervention were entered into a Cox regression model, technical failure (hazard ratio 
2.58; 95% CI 1.09-6-08), age (HR 1.06, 95% CI 1.019-1.103) and synthetic graft material (HR 
2.63; 95% CI 1-6.92) remained independent predictors of amputation during follow-up. 
  
At one month, the mortality rate was 6.5% (8/123). When entering age, smoking, hypertension, 
presence of acute limb ischemia, major haemorrhage and major amputation in a Cox regression 
model, higher age (HR 1.050; 95% CI 1.017 – 1.084), presence of acute limb ischemia (HR 
3.22; 95% CI 1.39 – 7.48) and major amputation (HR 2.63; 95% CI 1.41 – 4.90), remained 
independently associated with mortality. 
 
Amputation-free survival 
Figure 5 shows the crude Kaplan-Meier estimates of amputation-free survival for vein and 
synthetic bypasses. In a Cox regression model with age, hypertension, acute limb ischaemia and 
major haemorrhage as covariates, higher age (HR 1.06; 95% CI 1.03-1.09) and acute limb 
ischaemia (HR 2.4; 95% CI 1.26-4.56) remained independent negative predictors of amputation-
free survival.  
 
 
Figure 5: Kaplan-Meier estimates of amputation-free survival after thrombolysis 
 
  
DISCUSSION
This series of consecutive thrombolysis of occluded
lower limb bypass grafts from two large Swedish vascular
centers represents one of the largest published. The tech-
nical success rate was high, whereas the amputation rate
increased to 25% at 1 year, which is in line with a recent
published study from another tertiary vascular center.7
Unexpectedly, the present study showed that ischemic
heart disease was a factor for technical success of thrombol-
ysis. This finding was not related to group differences in
antithrombotic or anticoagulation therapy or type of graft.
Technical failure, higher age, and synthetic graft were
factors associated with major amputation during follow-up.
Some authors advocate a more selective approach toward
thrombolysis for occluded bypass grafts due to poor mid-
term results with high reocclusion rate and the inherent risk
of hemorrhagic complications.8
One advantage with successful thrombolysis over the
open surgical technique is that it allows an accurate assess-
ment of the vascular tree and underlying causes contribut-
ing to bypass graft failure. Indeed, the majority of patients
in this study underwent subsequent correction of an under-
lying stenosis within the graft and/or of an in- or outflow
stenosis. In addition, thrombolysis has been reported to
result in more patent outflow vessels compared with surgi-
cal thrombectomy.9 Pursuing endovascular treatment has
other advantages in this group of patients, who are often
elderly with multiple comorbidities. Surgical trauma is re-
duced, minimizing the inflammatory response, need for
analgesic medication, and immobilization, and there is also
a reduced risk of postoperative infection. An older prospec-
tive randomized trial of surgery versus thrombolysis for
occluded lower extremity bypass grafts showed that pa-
tients with acute limb ischemia with a duration of graft
occlusion of !14 days, randomized to thrombolysis, had
lower short-term amputation rates compared to surgical
patients.10 However, in the aforementioned study, it was
not possible to place a thrombolytic catheter in a high
proportion (39%) of patients who subsequently required
surgical revascularization. Since then, major advances in
endovascular treatment have been achieved, including in-
creasing skills and material knowledge by the intervention-
ists and technical development of catheters and other en-
dovascular tools.11
One should bear in mind that the selected patients in
this and probably in other studies on thrombolysis of bypass
grafts seem to be composed by grafts with an already
shortened life span. Synthetic grafts appeared to have a
somewhat increased likelihood of technically successful
thrombolysis compared with vein grafts, but on the other
hand they exhibited an increased risk of amputation during
follow-up. The latter finding has also been noted in previ-
ous studies.10,12 The assumed higher late occlusion rate of
synthetic grafts with subsequent higher amputation rate
Legs at risk:          39 (0.06)          32 (0.06)           23 (0.06)            16 (0.06)            12 (0.06)           4 (0.06)    vein graft
                               82 (0.04)          58 (0.05)            50 (0.05)            41 (0.06)            32 (0.06)          22 (0.07)   synthetic graft
P=0.10 
Fig. Amputation-free survival after thrombolysis for bypass graft occlusion in patients with lower limb ischemia.
Numbers below time axis denote limbs at risk in each group at respective time points. Standard error of cumulative
proportion leg surviving at end of interval is within parentheses. The tick marks indicate censored data.
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Discussion 
This cohort is one of the largest reported series of patients undergoing thrombolysis for bypass 
graft occlusion. The rates of amputation and technical success were similar to those of other 
contemporary series of thrombolysis for lower limb ischaemia.75, 76 When analysing factors 
associated with adverse outcomes, some findings were rather surprising. The association 
between ischaemic heart disease and technical success was possibly due to a statistical type I 
error related to a small sample size and the characteristics of the cohort (older individuals with 
multiple cardiovascular comorbidities), and did not appear to be caused by group differences in 
antithrombotic medication or graft type. 
 
Less surprising was the association between technical failure of thrombolysis and synthetic graft 
material and amputation. The fact that an increased severity of limb ischaemia on presentation, 
age and major amputation were associated with mortality was equally unsurprising. A higher 
degree of ischaemia may negatively affect outcomes by increasing the risk of reperfusion injury 
and by increasing the risk of complications during treatment, and it may also be a surrogate 
marker for more advanced vascular disease, which in itself is associated with mortality.  
The rate of intracerebral bleeding and major haemorrhage in this study is in line with existing 
literature.34  
 
Most patients in this study underwent some form of adjunctive procedure, and this may be partly 
caused by the ability to identify and correct any underlying culprit lesions. It has also previously 
been shown that thrombolysis gives a higher number of patent run-off vessels compared with 
open surgery.75 
 
The role of graft material on treatment success and longer-term outcomes remains somewhat 
unclear. In this study, synthetic grafts had a slightly increased likelihood of immediate technical 
success, but in the longer term they exhibited an increased risk of amputation. It has been 
postulated that the latter finding may be due to factors such as an increased risk of graft 
infection, ligation of collateral arteries and a history of previous vascular surgery in the same 
limb.77 The presence of a synthetic graft may also be a surrogate marker of inferior conditions 
for successful and durable vascular reconstruction, as a venous conduit is virtually always the 
preferred option if at all possible.  
 
The role of post-thrombolysis anticoagulation in order to prevent repeat occurrences is also not 
completely clear. Some authors have advocated the use of coumadin therapy78, but there is a 
paucity of evidence surrounding treatment strategies and duration.  
 
Because of its retrospective nature, this study suffers from several limitations. It was not 
possible to ascertain accurately the duration of symptoms prior to thrombolysis which may have 
been important for the outcome analysis, given that thrombus age may influence the 
susceptibility to thrombolytic degradation. Moreover, a longer duration of thrombosis may 
negatively affect the vessel wall of native conduits, reducing the likelihood of restoration of 
patency. In addition, there was no standardised protocol for graft surveillance and subsequent 
radiological patency data was not generally available. 
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Nonetheless, this study has shown that thrombolysis is a viable alternative for the treatment of 
infrainguinal bypass graft occlusion with acceptable rates of technical success and amputation-
free survival.  
  
  38 
4.2 RESULTS AND DISCUSSION STUDY II   
 
The purpose of Study II was to investigate if prior systemic thrombolysis (IVT) influenced 
outcomes after carotid endarterectomy (CEA) or carotid artery stenting (CAS) for the treatment 
of symptomatic carotid artery stenosis.  
 
Table 11: Demographics of the study cohort 
 
 
Patient characteristics 
The study included 3,998 patients who had undergone CEA or CAS for symptomatic carotid 
artery stenosis during the study period. Of these, 79 had undergone prior IVT. Table 11 shows 
the baseline characteristics of the study cohort. 
 
All patients in the thrombolysis cohort underwent IVT with rt-PA within 360 minutes of the 
onset of stroke symptoms (median 150 min, range 40 to 360 minutes). The median NIHSS score 
before thrombolysis was 8 (range 2 to 25) and after lysis the median score was 3 (range 0 to 18).  
 
Carotid surgery and stenting 
CEA or CAS was undertaken at a median of 10 days after IVT (range 0 to 108 days). Three of 
the 79 patients underwent CEA less than 48 hours after IVT. Fifty-seven of 79 underwent CEA 
or CAS within two weeks of IVT. In the control cohort (n=3919) the median time to CEA or 
CAS after the sentinel symptom was nine days (0 to178 days).  
 
  The majority (n=54) of the study patients underwent conventional CEA, 17 underwent eversion 
endarterectomy and six underwent CAS.  
  
Thrombolysis cohort 
N=79 
Non-thrombolysis cohort  
N =3919* 
P 
Median age (range) 71 (37-84) 73 (40-92) 0.04 
Gender (M/F) M 54/F 25 (68%;32%) M 2631/ F 1288 
(67%:33%) 
0.83 
Neurological presentation    
Minor stroke 46/79 (58%) 1344/3919 (34%) <0.00001 
Major stroke 33/79 (42%) 70/3919 (1.8%) <0.00001 
Current smoking 15/54 (28%) 759/3077 (25%) 0.60 
Treated for hypertension 60/79 (76%) 2923/3650 (81%) 0.36 
DM 21/79 (27%) 735/3650 (20%) 0.16 
Heart disease 19/67 (28%) 1117/3583 (31%) 0.62 
Previous stroke or TIA 24/79 (30%) 678/3698 (18%) 0.007 
Antithrombotic medication    
Aspirin only 36/78 (46%) NA  
Clopidogrel only 3/78 (4%) NA  
Dipyridamole only  3/78 (4%) NA  
Warfarin 1/78 (1.3%) NA  
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Complications and follow-up 
The rate of complications after CEA or CAS in the patients who had received IVT was similar to 
that seen in the control group who had not undergone thrombolysis. The 30-day death and stroke 
rate was 2.5% after IVT and 3.8% in the control group (P=0.79). Table 12 summarises the 
frequencies and types of complications seen in the two cohorts, and Table 13 shows the 
characteristics of the patients in the IVT group who had suffered complications.  
 
   Table 12: Complications after CEA/CAS in the two cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
✝P=0.03; Thrombolysis cohort vs. nonthrombolysis cohort.  
‡Death not included in the total complication rate 
 
 
 
 
Table 13: Characteristics of patients suffering complications after IVT and CEA/CAS 
 
 
Complications Thrombolysis 
cohort (n=79) 
Non-thrombolysis cohort  
(n=3,919*) 
Total number of complications✝ 5/79 (6.3%) 551/3626 (15%) 
Minor stroke 2/79 (2.5%) 62/3626 (1.7%) 
Major stroke 0 46/3626 (1.3%) 
TIA 0 42/3626 
Cerebral hemorrhage 0 27/3626 
Cranial nerve injury 0 175/3626 
Reoperation for surgical site 
bleeding 
3/79 (3.8%) 119/3626 (3.3%) 
Myocardial infarction 0 54/3626 (1.5%) 
Death within 30 days‡  
 
0 31/3626 (0.9%) 
Patient  Age Sex Complication type Days from 
trombolysis 
Indication Type of surgery 
1 64 M Reoperation for 
bleeding 
1 Minor stroke Conventional 
CEA 
2 81 M Retinal infarction 3 Minor stroke Conventional 
CEA 
3 78 F Reoperation for bleeding 4 Minor stroke Conventional 
CEA 
4 81 M Minor stroke 5 Major stroke Conventional 
CEA 
5 83 F Reoperation for bleeding 6 Minor stroke Eversion CEA 
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Having undergone IVT did not influence the overall 30 day postoperative complication rate 
(P=0.072). 
  
There was no association between the time from IVT to subsequent CEA/CAS (P=0.189), and 
patients undergoing CEA/CAS within two weeks of IVT were not more likely to suffer any 
complications (P=0.15).  
 
Discussion 
This population-based study did not show an increased rate of complications following CEA or 
CAS. At the time, it was the largest reported cohort of patients undergoing CEA/CAS after IVT, 
demonstrating the unique opportunity for analysis of a small but increasing cohort that is 
afforded by the national vascular surgery and stroke registries. The compound 30-day stroke and 
death rate of 2.5% in the IVT cohort was in line with that seen in the control cohort (3.8%). 
There were no haemorrhagic strokes seen in the IVT group.  
 
Interestingly, all patients who suffered complications underwent CEA/CAS within one week of 
IVT (as can be seen in Table 3). It is unclear whether this was associated with IVT, or more 
generally related to the timing of carotid intervention after the qualifying event. As reported by 
Strömberg and colleagues79, very early CEA may increase procedural risk with a death and 
stroke rate of 11.5% if surgery was undertaken within 48 hours of the neurological event. This 
fell sharply to 3.6% for those patients who were operated on after three days but within seven 
days.  
 
No increase of bleeding-related complications was detected when comparing the IVT group with 
the control group (3.8% versus 3.3%; P=0.79). However, given the short half-life of rt-PA in 
plasma of five minutes69, it is not clear whether rt-PA affects haemostasis in patients within the 
time-frame of CEA/CAS being offered. As a comparison, in patients undergoing coronary artery 
bypass grafting (CABG) after IVT with streptokinase for myocardial infarction, an increase in 
bleeding and requirement of blood products was seen in those patients whose surgical procedure 
was undertaken 12 hours or less after cessation of thrombolysis. As with rt-PA, SK induces a 
fibrinolytic state with consumption of fibrinogen, and the replenishment of fibrinogen stores 
may take up to 24 hours because of the rate of fibrinogen synthesis.69  
 
This study suffers from several limitations, owing to its retrospective design and small study 
population. Data from the national registries was not complete, although previous validation 
studies have shown excellent external and internal validity.80, 81 
 
The small number of patients having undergone prior IVT makes a type II statistical error more 
likely, and also makes it difficult to draw any conclusions regarding the role of CAS in this 
group of patients, as there were only six patients who were treated by this method. 
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However, this study has demonstrated that carotid surgery and stenting may be safely 
undertaken in patients having undergone IVT for stroke. Future studies should focus on timing 
of the carotid intervention after IVT and patient selection.   
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4.3 RESULTS AND DISCUSSION STUDY III 
 
The aim of this study was to compare the outcomes of an ‘endovascular first’ approach with a 
‘surgery first’ approach for treating the first episode of dialysis access thrombosis.   
 
Patient and dialysis access characteristics 
During the study period there were 131 patients presenting with 149 episodes of primary 
thrombosis of an AVF or an AVG. The mean age of the patients was 65 years (SD 12.8 years; 
range 31 to 89 years); 40% were female. Table 14 summarises the characteristics of the study 
cohorts (thrombolysis and open surgery). There were no significant differences in characteristics 
except for a lower proportion of females in the thrombolysis group and an increase in diabetic 
nephropathy and nephrosclerosis in the same group compared with the open surgery group.  
 
Table 14: Patient characteristics 
 Thrombectomy 
n=90 
Thrombolysis 
n=41 
Overall 
n=131 
P 
Age (Median, range) 65 (31-88) 65 (39-89) 65 (SD 12.8; 
median 65) 
0.86 
Women (%) 41 (46) 11 (24) 52 (40)     0.02** 
DM (%) 29 (32) 22 (54) 51/131 (39) 0.09 
Cardiac risk (%) 27 (30) 12 (29) 39/131 (30) 0.51 
On-going smoking (%) 11 (12) 4 (10) 15/131 (12) 0.58 
Previous stroke/TIA 
(%) 
10 (11) 7 (17) 17/131 (13) 0.40 
Renal pathology     
DM nephropathy (%) 22 (24) 18 (45) 40/131 (31)   0.04** 
Polycystic kidney 
disease (%) 
13 (14) 3 (7) 16/131 (12)          0.39 
Glomerulonephritis 
(%) 
22 (24) 4 (10) 26/131 (20) 0.06 
Nephrosclerosis (%) 5 (6) 8 (20) 13/131 (10)     0.02** 
Hypertensive 
nephropathy (%) 
11 (12) 0 11/131 (8)     0.02** 
Post nephrectomy (%) 4 (4) 0 4 /131(3)  0.31 
Other (%) 13 (14) 8 (20) 21/131 (16) 0.45 
Antithrombotic 
medication  
    
Single platelet 
antagonist (%) 
22 (24) 13 (32) 35/131 (27) 0.40 
Double platelet 
antagonist (%) 
 
             4 (4) 0 4/131 (3)             0.31 
Low molecular weight 
heparin (%) 
 
             4 (4) 0 
 
3/131 (3)              0.31 
Anticoagulant drug 
(%) 
             15 (17) 
 
6 (15) 
 
21/131 (16)  
1.0 
None (%) 43 (48) 21 (51) 64/131 (49)   0.85 
Unknown (%) 2 (2) 1 (2) 3/131 (2) 1.0 
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There were 149 episodes of dialysis access thrombosis, of which 107 were treated with open 
surgical thrombectomy and 42 with thrombolysis. Table 15 shows the distribution of different 
access types across the treatment groups.  
 
Table 15: Access types in the study cohort 
*E.g. straight forearm grafts 
** E.g. straight grafts, brachio-basilic transpositions 
 
The dialysis accesses were treated for thrombosis at a median of 6.5 months after initial creation 
with an interquartile range of 17 months. This did not differ significantly between the groups 
(P=0.23). 
 
Technical success and adjunctive procedures 
Technical success was achieved in 96 of 149 total cases (64%). The success rates were 66/107 
(62%) in the open group and 31/42 (74%), which was not significantly different (P=0.18).      
Adjunctive procedures at the time of the study intervention were used in 61% (n=65/107) of the 
patients in the open group and in 88% (n=37/42) in the thrombolysis group, which was 
significantly different (P=0.001). Table 16 details the type of adjunctive procedures undertaken 
in conjunction with the study intervention. Some patients had more than one adjunctive 
intervention performed.  
 
Table 16: Adjunctive interventions 
Type of adjunct Thrombectomy (N=107) Thrombolysis (N=42) 
Balloon angioplasty 16 34 
Open anastomotic revision 26 4 
Open interposition grafting 15 1 
Stent/stent graft 2 2 
Change of graft limb 6 0 
Unknown 2 0 
 
As discussed in section 3.5, the outcome patency time was the post-intervention primary 
assisted patency time. Several patients therefore had assistive procedures performed to maintain 
their dialysis access after the initial thrombolysis or thrombectomy, and these are detailed in 
Table 17.  
 Thrombectomy 
(n=107) 
Thrombolysis 
(n=42) 
P 
Access anatomy N(%) N (%)  
Radio-cephalic  12 (11) 7 (17) 0.42 
Brachio-cephalic 9 (8) 2 (5) 0.73 
Loop graft 39 (36) 16 (38) 0.85 
Other lower arm * 15 (14) 4 (10) 0.59 
Other upper arm ** 32 (30) 13 (31) 1.0 
Access material    
Native vein 27 (25) 14 (33) 0.32 
Synthetic 80 (75) 28 (67) 0.32 
  44 
Table 17: Subsequent assistive procedures after thrombolysis or thrombectomy 
 
Complications 
There were few adverse events observed in the study cohort. Four patients in the open surgical 
group developed a postoperative surgical-site infection, three of which could be treated with 
antibiotics. There were no cases of significant bleeding, myocardial infarction or stroke.  
 
Access patency 
Figure 6 shows the crude Kaplan-Meier patency curves for each of the treatment groups 
(defined in section 3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: 
Crude 
Kaplan-Meier 
curves of 
access patency 
 
 First  
procedure  
(n=38) 
Second 
procedure 
(n=15) 
Third 
procedure 
(n=9) 
Fourth 
procedure 
(n=2) 
Balloon 
angioplasty 
26 7 3 1 
Anastomotic 
revision 
6 0 2 1 
Interposition 
grafting 
4 2 1 0 
Stenting 
 
1 6 3 0 
Diagnostic 
Angiography 
1 0 0 0 
Median time 
in months 
(range) 
5 (0-27) 9 (2-32) 21 (5-40) 11 (7-14) 
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The risk of rethrombosis was analysed over time following the study intervention. Patients were 
divided into four groups depending on type of treatment and access material as described in 
section 3.5. In order to provide a relevant comparison, the analysis was limited to those patients 
who had undergone an adjunctive intervention. Figure 7 shows the modelled risk of reocclusion 
for each of the groups, and as indicated in Figure 7, the lowest risk was seen in AVFs after 
initial thrombolysis, followed by AVFs after open surgery and then AVGs undergoing 
thrombolysis. The highest risk of reocclusion was seen in AVGs after open surgery. The average 
risk increase between each treatment group was 41% (95% CI 0.4% to 98%) after correcting for 
sex, diabetes and fistula anatomy. Figure 7 shows a graphical representation of the risk of 
rethrombosis per treatment group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Hazard curves for individual treatment groups. There is a 41% (0.41; 95% CI 0.4% to 
98%) increase in risk for rethrombosis between each treatment group after adjusting for 
potential confounders 
 
Discussion 
This study has demonstrated an improved patency after thrombolysis for both AVFs and AVGs. 
Unsurprisingly, more patients in the endovascular group underwent adjunctive procedures in 
conjunction with the initial thrombolytic treatment, which would have influenced the outcome. 
However, the difference between the groups remained even after limiting the analysis to those 
patients who had undergone such additional procedures, suggesting that thrombolysis does 
confer an advantage independent of the increased ability to visualise fistula anatomy and identify 
any underlying culprit lesions. Following on from the above, the patency was better overall for 
native fistulas compared with grafts, an outcome that has also been noted in other studies.82, 83 
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The complication frequency in this series was low, without any incidences of major 
haemorrhage. A contributing factor may have been that only the first episode of thrombosis for 
each AVF or AVG was studied. Increasing access usage with repeated puncture may possibly 
increase the risk of bleeding compared with a younger access that may not have been used prior 
to thrombosis. However, the study accesses were of varying ages and many had been used for a 
significant length of time, so it is not possible to attribute the low risk of bleeding observed 
solely to access age and usage in this series. Importantly, there was no significant difference in 
access age between the endovascular and open groups, which could have biased the outcome of 
the study.  
 
One of the main limitations of this study is the absence of a formalised treatment protocol for 
dialysis access thrombosis at the participating centres. This could have influenced patient 
selection and makes the groups more heterogenous. Intraoperative angiography was not 
routinely performed, something which may have improved the outcomes seen in the 
thrombectomy group. It has previously been recommended that such imaging be routinely 
performed during open surgical procedures for access thrombosis.84 Its retrospective nature and 
the way in which thrombolytic therapy is documented in the medical records made a robust 
calculation of the total dose administered of rt-PA impossible, which could have been a factor 
affecting the results. Unfortunately, the same reason made it impossible to record accurately the 
duration of access thrombosis prior to the study intervention, something which has been shown 
by Sadaghianloo and colleagues to influence outcomes, with improved results seen in very early 
thrombectomy.85 Moreover, the number of patients was relatively small, which could have 
contributed to a statistical type II error.  
 
Nonetheless, this study has showed an advantage of thrombolysis over open surgical 
thrombectomy for the treatment of thrombosis of both AVFs and AVGs, with an improvement 
in freedom from reocclusion that appears independent of any adjunctive procedures. Further 
studies should focus on the timing of treatment and the role of adjuncts such as 
pharmacomechanical thrombolysis in re-establishing access patency after thrombosis.  
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4.4 RESULTS AND DISCUSSION STUDY IV 
This study aimed to investigate if and how the level of inpatient care during catheter-directed 
thrombolysis (CDT) affected safety-related outcomes. A secondary aim was to identify risk-
factors associated with patient transfer to a higher level of care during CDT.  
 
Patient characteristics and indications for thrombolysis 
Two hundred and eighty-one episodes of CDT in 252 patients were recorded at the two 
participating centres during the study period (116 on the general vascular ward (Centre 1) and 
136 on the postoperative recovery unit (Centre 2). Table 18 shows a summary of the 
characteristics of the study population across the two centres.  
 
Table 18: Demographics of the study cohorts 
 Centre 1 N=116 Centre 2 N=136 P 
Female (%) 52 (45) 63 (46) 0.90 
Age median (range) 73 (62) 69 (69) 0.13 
DM (%) 44 (38) 37 (27) 0.08 
Cardiac (%) 51 (44) 53 (39) 0.44 
Cerebral (%) 16 (14) 17 (13) 0.85 
Hypertension (%) 72 (62) 85 (63) 1.0 
Renal insufficiency** (%) 15 (13) 12 (9) 0.21 
Current smoking (%) 18 (16) 35(26) 0.03* 
Indication (lower limb/dialysis 
access/upper limb)§ 
101/26/0 139/12/4  
Acute extremity ischemia (%)§ 96 (76) 82 (82) 0.3 
Antithrombotic medication§ (%)    
Warfarin 16 (13) 16 (10) 0.57 
Aspirin 64 (50) 86 (55) 0.55 
Novel Oral Anticoagulant 0  3 (2) 0.26 
Limb viability§§ (%)    
Category I 95 (95) 108 (78)  
<0.00001* Category IIa 5 (5) 26  (19) 
Category IIb 0 5 (3.6) 
Iatrogenous embolization (%)§ 24 (19) 5 (3) <0.0001* 
*P<0.05 
**Excluding patients undergoing thrombolysis for dialysis access thrombosis 
§All thrombolysis episodes (n=281) 
§§Only thrombolysis for limb ischaemia (N=239) 
 
The majority of patients underwent CDT for limb ischaemia (240/281 episodes; 85%). Two-
hundred and twenty-three of 281 episodes (79%) were conducted for acute symptoms (<14 
days’ duration). It is noteworthy that iatrogenous embolisation during another endovascular 
procedure was significantly more common at Centre 1 than Centre 2.  
 
Outcomes of thrombolysis 
Overall success of CDT was achieved in 78% (218/281) of cases and the median duration of 
treatment was 20 hours with no difference between centres (P=0.89). Vascular access was most 
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often in the groin (238/281). Compartment syndrome after CDT for limb ischaemia was noted in 
4.6% (11/240).  
 
Bleeding and other complications 
Bleeding of any severity was observed in 32% of patients (89/281). More patients on the general 
vascular ward had reported low-level bleeding (category 1 and 2) compared with those on the 
postoperative recovery unit (29/126 versus 14/155; P=0.002), but there was no difference in 
major bleeding (category 3 and above) between the groups (7/126 versus 3/155, P=0.12). Table 
19 details the types and frequencies of complications observed in the groups. 
 
Table 19: Complications of thrombolysis 
 Centre 1 (N=126)  
(%) 
Centre 2 (N=155) 
(%) 
P 
Conversion to open 
surgery/amputation 
12 (9.5) 19 (12) 0.63 
Acute myocardial infarction 3 (2.4) 3 (1.9) 1.0 
Ischaemic stroke 1 (0.8) 2 (1.3) 1.0 
Haemorrhagic stroke 0 2 (1.3) 0.5 
Intractable pain 12 (9.5) 11 (7.3) 0.52 
Severe confusion 6 (4.7) 4 (2.6) 0.34 
Other    
Renal failure 2 (1.6) 6 (3.9) 0.3 
Hospital-acquired pneumonia 2 (1.6) 2 (1.3) 1 
Sepsis 1 (0.8) 3 (1.9) 0.63 
GI bleeding 2 (1.6) 1 (0.6) 0.59 
Hypofibrinogenaemia 1 (0.8) 2 (1.3) 1 
Multi-organ failure 0 2 (1.3) 0.5 
Death 1(0.8) 1(0.6) 1.0 
Bleeding (%)    
Class 0 70 (56) 122 (79)  
Class 1 29 (23) 14 (9)  
Class 2 20 (16) 16 (10)  
Class 3a 7 (6) 3 (1.9)  
Compartment syndrome 5 (3.9) 6 (3.9) 0.76 
Transfer to higher level of care 
(% of whole cohort) 
 
Confusion  
Other complication 
Lack of resources on ward 
Unknown   
17 (13) 7 (4.5) 0.01* 
6 /17(35) 0  
4 /17(24) 7/7 (100)  
6/17 (35) n/a  
1/17 (6) 0  
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There were no differences in the frequency of non-bleeding related complications between 
patients who had undergone CDT on the general vascular ward compared with those on the 
postoperative recovery unit. There were two haemorrhagic strokes (0.7%) in the cohort. Eleven 
per cent (31/281) of cases required conversion to open surgery or amputation during the same 
inpatient episode. There were two deaths in the cohort (one at each centre), relating to ischaemic 
stroke and multiorgan failure respectively.  
 
Transfer to a higher level of care 
In total, 24 patients were transferred to a higher level of care across both centres (8.5%).  
Patients on the vascular ward were more likely to require transfer to a higher level of care during 
CDT than those on the postoperative recovery unit (P=0.001). Table 20 displays the 
characteristics of the transfer patients compared with those who did not require transfer.  
 
Table 20: Characteristics of patients transferred to a higher level of care 
 
 
Transfer (N=18) Non-transfer (N=257) P 
Age (mean, SD) 76±11 69±13 0.04* 
Female (%) 13/18 (72) 117/257 (46) 0.03* 
DM (%) 5/18 (28) 82/257 (32) 0.80 
Duration of 
thrombolysis 
22.1h 22.8h 0.68 
Cardiac (%) 13/18 (72) 100/257 (39) 0.01* 
Cerebral (%) 5/18 (28) 30/257 (12) 0.06 
Hypertension (%) 11/18 (61) 160/257 (62) 1.0 
Current smoking 
(%) 
3/18 (17) 55/257 (21) 0.58 
Indication (%)    
Limb ischaemia 16/18 (89) 218/257 (85)  
1.0 Dialysis access 2/18 (11) 35/257 (14) 
Arm ischaemia 0 4/257 (1.6) 
 
The differences observed between the two groups were increasing age, a higher proportion of 
females and the presence of cardiac disease in the transfer cohort. When these variables were 
entered into a logistic regression model, cardiac disease remained as an independent risk factor 
for transfer (OR 3.2; 95% CI 1.04-9.8; P=0.04).  
 
Discussion 
To our knowledge, this is the only study that has directly examined the influence of patient level 
of care on the safety of CDT. In Sweden, most vascular surgical patients undergoing CDT are 
cared for on a high-dependency unit86 and there is a paucity of evidence surrounding the subject.  
 
In this study, no systematic differences were detected in patient characteristics between the two 
centres that may have themselves explained the observed outcomes. The frequency of bleeding 
and other complications was similar to previously reported numbers.34, 76, 87  
A strength of this study is the joint treatment protocol for CDT that is employed by both 
participating centres. Moreover, the organisation of services is such that there is an overlap of 
  50 
the vascular surgeons and interventional radiologists performing CDT at both hospitals, reducing 
the risk of bias.  
 
The limitations of the study include its retrospective design and relatively small cohort (n=252), 
and the low frequency of the study end-points.  
 
In conclusion, this study has shown that a lower level of care (general vascular ward) does not 
significantly increase the risk of adverse events during CDT for limb ischaemia and dialysis 
access thrombosis compared with a high-dependency unit, provided appropriate patient selection 
and adequate training of nursing staff. Future work should address the cost-benefit implications 
and logistical consequences of differing levels of care on the provision of CDT.  
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5  GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
 
The works included in this thesis have examined different aspects of thrombolytic treatment in a 
large and diverse group of patients within the context of vascular surgery. The overall aim was 
to investigate the outcomes of thrombolytic treatment in some of the most commonly seen 
patient groups, and the resulting heterogeneity is reflective of the clinical questions facing 
vascular surgeons and interventional radiologists on a daily basis. 
 
The huge increase in the popularity of endovascular methods for the treatment of peripheral 
vascular disease has brought significant advances in both techniques and materials, enabling the 
clinician to treat more patients in this way than ever before. An important advantage of the 
endovascular approach is reduced invasiveness, which also opens the possibility of treating 
patients who would otherwise not be offered vascular surgery.  
 
Furthermore, the development of more rapid-acting and specific thrombolytic agents (with a 
reduced risk of unwanted remote bleeding) may also increase the clinical utility of thrombolysis 
and broaden the indications for its use. However, the ‘ideal thrombolytic agent’ is yet to be 
found.  
 
The topics in this thesis concern clinical outcomes such as limb salvage and vascular/conduit 
patency (Study I and III), as well as safety-related end-points such as the development of 
complications (Study II and IV). 
  
Retrospective analysis of data from national registries and medical records affords a relatively 
quick assessment of the parameters of interest, but will always be hampered by the quality of 
data input and the possibility of irreconstructible incompleteness of information. It is apparent 
from this and other studies that clinical end-points can be determined reasonably accurately from 
retrospective scrutiny of collected data, and that nationwide registries afford the researcher a 
unique opportunity to study smaller subgroups of patients or outcomes with low event-rates. 
However, this does not obscure the need for further prospective research into the questions 
posed by this thesis. 
 
The role of CDT in the treatment of infrainguinal bypass graft occlusion was addressed in Study 
I, where acceptable limb-salvage rates were observed in the cohort. Although less invasive than 
open surgery, CDT can be a relatively time-consuming affair. This somewhat limits its 
applicability, as patients who have immediately threatened limbs (i.e. where the degree of 
ischaemia is so severe that there is a risk of limb loss unless the extremity is revascularised 
immediately) require quicker results than the method can afford. There have therefore been 
numerous attempts to develop adjuncts to CDT to enhance its effect and quicken its onset of 
action.  
 
Based on the currently available evidence, rheolytic thrombectomy (RT), a form of 
pharmacomechanical thrombolysis, could be considered the most promising.88 Rheolytic 
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thrombectomy can be used either as a stand-alone method for thrombus clearance or as an 
adjunct to CDT in order to debulk thrombus and thereby possibly reduce the time required to 
clear the thrombotic material. It can also be used for the delivery of thrombolytic agent via the 
PowerPulse method.89  
 
In a very recent report by Leung and colleagues90, the AngioJet® device was evaluated in the 
treatment of acute limb ischaemia in 283 patients in a multi-centre prospective observational 
study. Patients were treated with either RT only or with RT and CDT. Those who had undergone 
RT only exhibited higher rates of amputation-free survival compared with those who also 
underwent CDT (P=0.017). The RT-only group also had a significantly shorter procedure 
duration compared with the RT+CDT cohort (1.6h versus 23h; P<0.001). In this study there was 
a significant proportion (35%) of patients with immediately threatened limbs (Rutherford class 
IIb91 and above), and these were more likely to undergo RT together with CDT, which may in 
part explain the observed difference in amputation-free survival.  
 
The development of further methods to augment CDT may in a longer-term perspective enable 
the treatment of patients whose limbs would otherwise not be salvageable using traditional CDT 
only, and where open surgery may not be possible.  
 
The small but increasing group of patients being treated with IVT before carotid intervention for 
stenosis of the carotid artery is also an example of the need for further large, multi-centre 
prospective registries to enable more robust analysis of the outcomes. At the time of publication, 
Study II was the largest reported series with 79 patients. Subsequently, a Nordic collaboration 
published the results of a retrospective registry study of 202 patients who underwent CEA after 
IVT (in which the majority of patients from Study II were included).43 Of these, only 117 had 
undergone CEA within 14 days of their qualifying neurological event, and similar to the findings 
in Study II in this thesis, these authors did not demonstrate an increase in adverse events in the 
IVT patients. However, this study suffered from significant gaps in data owing to its 
retrospective design and the constraints imposed by the amount of information collected in each 
of the participating registries, which somewhat limits the conclusions that can be drawn from the 
report.  
 
Taken together, the available evidence points to the conclusion that IVT does not negatively 
influence the outcomes after CEA for symptomatic carotid artery stenosis. However, the 
evidence for timing of the procedure remains weak, and further prospective work should be done 
to quantify the risks associated with very early procedures.  
 
The difficulty in assessing clinically relevant outcomes in a population reflective of that seen in 
everyday vascular surgery practice is highlighted by Study III, where there is a significant 
heterogeneity in many of the patient-related variables, as well as in the type of dialysis access 
studied. It also highlights the difficulties in determining a clinically useful measure of patency. 
In this study, a composite patency measure defined as the time between completion of surgery or 
thrombolysis and the next episode of clinically verified thrombosis was used. According to 
current reporting standards73, this was the post-intervention primary assisted patency.  
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It is possible to divide the patency time into several subsegments based on any further 
interventions that are done to maintain fistula function. However, although this may be a more 
stringent method, it complicates the survival analysis and may be less clinically relevant, as it is 
the next episode of thrombosis that has the biggest impact on patient care. Moreover, there was 
no consistently available data on access surveillance. Many authors51, 92 have used the 
Transonic® ultrasound dilution method for interim surveillance of AVF/AVG function, and 
such measurements often guide clinical decision-making concerning the need for assistive 
procedures such as balloon angioplasty or open revision of the access.  
 
Nonetheless, Study III does demonstrate the potential for improved outcomes using an 
endovascular-first approach, although more research into the role of newer adjuncts such as 
drug-eluting balloons, augmented systemic anticoagulation and platelet inhibition is required, as 
well as further development of hybrid (combined open and endovascular) techniques in dialysis 
access management.   
 
The role of inpatient care during thrombolysis is an area which has not been studied extensively, 
despite the increasing popularity of catheter-based techniques, and to date there have been no 
published studies of the influence of patient monitoring on adverse outcomes during CDT. This 
thesis has demonstrated that, given adequate training of nursing staff and patient selection, a 
regular vascular ward can provide safe care for patients undergoing CDT both for limb 
ischaemia and dialysis access occlusion. Patients with significant comorbidity (in particular 
cardiac disease), advancing age and possibly also women are however more likely to require a 
higher level of care, which demonstrates the importance of careful patient selection.  
 
The findings in this study could have an impact on the utilisation of healthcare resources, 
simplifying logistics surrounding patient care and may lead to reduced costs. In a recent study of 
the cost-effectiveness of an endovascular (CDT) versus an open surgical approach for the 
treatment of acute limb ischaemia, Lurie and colleagues93 found that the costs associated with 
endovascular treatment by far exceeded those associated with open surgery ($34,800 versus 
$10,677). The increase in costs for CDT in this study was attributable in part to higher intensive 
care unit costs in this group. These findings underline the importance of re-evaluating existing 
treatment protocols in order to ensure the best utilisation of available resources while 
maintaining the highest level of patient safety.  
 
Taken together, the results of the studies included in this thesis show that thrombolysis is a safe 
and efficacious treatment in many contexts within vascular surgery. There is nonetheless a need 
for more prospective research into the safety and outcomes of endovascular treatment methods 
in this large group of patients, especially considering the very fast development of techniques 
and devices. This also poses questions to clinicians regarding resource utilisation, and it is 
important that the costs of these new methods are adequately analysed upon implementation in a 
public healthcare system. 
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The role of pharmacomechanical thrombolysis also needs to be further evaluated, especially in 
the context of offering endovascular treatment for severe acute limb ischaemia in cases where 
open surgery may not be possible.  
 
Furthermore, the question of how to ensure optimum results after successful re-establishment of 
vascular patency remains, and further research should be aimed at investigating the role of 
adjunctive medical treatment after thrombolysis. 
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6 CONCLUSIONS 
 
 
§ Catheter-directed thrombolysis for the treatment of acute infrainguinal bypass graft 
occlusion results in good amputation-free survival with relatively few serious 
complications. Synthetic bypasses exhibit a slightly higher immediate technical success 
rate, but in the longer term, native grafts tend to do better. 
 
§ The administration of intravenous thrombolysis does not seem to cause an increase in 
adverse events and complications seen after CEA or CAS in patients with symptomatic 
carotid artery stenosis, although the risk of very early procedures (within three days of 
the qualifying neurological event) needs further evaluation. 
 
§ Compared with open surgery, CDT of a native or prosthetic dialysis access yields a 
lower risk of rethrombosis even when removing the influence of adjunctive procedures. 
Autologous fistulas appear to fare better than prosthetic grafts after both open surgery 
and thrombolysis. 
 
§ When evaluating safety-related outcomes of CDT in patients with limb ischaemia or 
dialysis access occlusion,  a lower level of care as provided on a general vascular ward 
was not associated with an increase in adverse events compared with the higher level of 
care provided on a postoperative recovery unit wth continuous monitoring of 
physiological parameters. Cardiac disease was an independent risk factor for transfer to 
a higher level of care, and age and female gender may also increase the likelihood of 
transfer. These findings could help in selecting appropriate patients for CDT and may 
have an implication for healthcare-associated costs and resource utilisation.  
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7 SAMMANFATTNING PÅ SVENSKA 
 
Användning av propplösande läkemedel, s.k. trombolys har under de senaste 20 åren blivit 
mycket vanligt i behandlingen av patienter med plötsligt cirkulationsbortfall i ben eller arm, 
stroke, hjärtinfarkt eller djup ventrombos. Denna typ av behandling kan ges antingen 
ospecifikt in i blodet som vidare transporterar den propplösande substansen till det drabbade 
kärlet (intravenös trombolys) eller via en kateter direkt in i själva blodproppen (kateterledd 
trombolys). Dessa behandlingsmetoder har visat sig minska risken för bestående men hos 
patienter med stroke. När det gäller intraarteriell kateterledd trombolys innebär detta vanligen 
en skonsammare metod för patienten som om behandlingen lyckas inte behöver genomgå ett 
större kirurgiskt ingrepp på sitt ben eller arm för att återställa cirkulationen.  
 
Syftet med denna avhandling var att se hur trombolys påverkar utfallet hos olika grupper av 
patienter med kärlsjukdom. Mer specifikt undersöktes (I) hur utfallet efter propp i kärlgraft i 
benen påverkades av trombolysbehandling, (II) om trombolysbehandling för stroke ökade 
risken för komplikationer hos patienter som sedermera behandlades med operation av 
halspulsådern p.g.a. åderförkalkning, (III) hur det går för patienter som drabbas av stopp i 
fistlar för dialysbehandling p.g.a. njursvikt som behandlas antingen med sedvanlig operation 
eller kateterledd trombolys och slutligen (IV) vilken roll vårdavdelningen på sjukhus spelar 
för de patienter som genomgår intraarteriell trombolysbehandling för blodpropp i benen eller 
stopp i dialysfistlar. Generellt har patienter som genomgår sådan behandling vårdats på en 
intensivvårdsavdelning eller en intermediärvårdsavdelning som har en högre personaltäthet 
och mer övervakning av fysiologiska parametrar som t.ex. blodtryck och puls.  
 
Man kan dela upp studierna i två generella grupper: Studier av det kliniska resultatet av 
trombolysbehandling avseende behandlingsframgång och risk för återfall (I och III) samt 
studier av säkerheten av trombolysbehandling avseende komplikationer hos patienterna (II 
och IV).  
 
Studie I visar att trombolys gav ett bra resultat avseende behandlingsframgång, i över 80 % 
av fallen gick det att lösa upp proppen i kärlgraftet på benet. Risken för amputation av det 
drabbade benet var låg både efter en månads och ett års uppföljning. Äldre patienter och 
patienter där det inte gick att lösa proppen hade en högre risk för amputation och död.  
 
I studie III innebar trombolys en lägre risk för nytt stopp i dialysfistlar jämfört med om 
patienten hade genomgåtten vanlig operation. Fistlar gjorda av konstgjort material hade 
sämre behandlingsframgång och en ökad risk för nytt fistelstopp.  
 
Studie II visade att föregående trombolys inte gav någon ökad risk för komplikationer hos 
patienter som genomgår operation av halspulsådern p.g.a. åderförkalkning och slaganfall 
(stroke). Risken för död eller stroke efter operation var 2.5% i gruppen som hade behandlats 
med trombolys jämfört med 3.8% för patienter som inte hade behandlats med trombolys men 
genomgått samma typ av operation.  
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Studie III visade att vård på en vanlig vårdavdelning för kärlkirurgi inte gav någon ökad risk för 
komplikationer under pågående intraarteriell kateterledd trombolys jämfört med vård på en 
avdelning med en högre grad av övervakning av patienterna och med högre personaltäthet. 
Andelen av komplikationer som blödning, hjärtinfarkt och stroke var samma hos båda 
grupperna.  
 
Sammanfattningsvis påvisar resultaten i denna avhandling att trombolys är en säker 
behandlingsmetod som ger goda resultat avseende behandlingseffektivitet och risk för återfall av 
blodpropp i det behandlade kärlet. Att vårda selekterade patienter på en vanlig kärlkirurgisk 
avdelning under trombolysbehandling är inte förknippat med ökad risk för komplikationer vilket 
kan ha en stor betydelse för resursfördelning inom vården samt vårdkostnader.  
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